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1. INTRODUCTION
In consequence of their biological eﬀects, conformationally
constrained carbocyclic β-amino acids have generated great
interest among synthetic and medicinal chemists in the past 2
decades, and they have become a hot topic in organic and
bioorganic chemistry. These compounds are found in natural
products and antibiotics. They are also considered important
precursors for pharmacologically interesting β-lactams and
other bioactive compounds. Certain carbocyclic β-amino acids,
e.g., cispentacin (1), icofungipen (2), and BAY Y9379 (3),
possess noteworthy antifungal or antibacterial activities, while
tilidin (4), a phenyl-substituted cyclohexene amino ester, is an
analgetic (Figure 1).1,2a−d
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Carbocyclic β-amino acids are also important elements in
many products with interesting pharmacological potential.
Several of them are depicted in Figure 2. Amipurimycin (5) and
pitucamycin (6), containing ﬁve- and six-membered carbocyclic
β-amino acid moieties, are antibiotics, while compounds 7−11
possess enzyme-inhibitory and antitumoral activities.2e−k
Since these compounds may be applied as building blocks in
peptide synthesis, the incorporation of novel conformationally
restricted β-amino acids into peptides, and especially foldamers,
has attracted considerable interest from the aspect of the
preparation of peptide-based drug molecules with high
biological potential.3,4
As a result of the immense progress made in the ﬁeld of
carbocyclic β-amino acids, a high number of original papers and
reviews (around 200) have been published on this topic in the
past 10 years. Since the most recent comprehensive survey of
the synthesis and chemistry of β-aminocycloalkanecarboxylic
acids was published over a decade ago (Chemical Reviews,
20011a), we consider that there is a great need for an updated
coverage of the subsequent relevant synthetic advances,
particularly those concerning the synthesis of such derivatives
in enantiomerically pure form, together with other important
chemical aspects in this developing area of organic and
medicinal chemistry.
Besides these carbocyclic compounds, conformationally rigid
cyclic β-amino acids containing a heteroatom (nitrogen or oxygen)
in the ring and with the carboxylic and the extracyclic amino
functions attached to stereogenic C-centers on the skeleton have
likewise received signiﬁcant attention in recent years as a result
of their biological importance, and chemical interest in these
medicinally relevant molecules has increased rapidly.5 Despite
the rising number of publications on these heterocyclic β-amino
acids (almost 200 references in the past 15 years), no
comprehesive, systematic overview has appeared, so far, on
the syntheses and applications of this valuable class of
compounds in the ﬁeld of amino acids. Accordingly, a
comprehensive description of the synthetic routes with an
account of the main biological activities appears highly
necessary.
A considerable number of syntheses of carbocyclic and
heterocyclic β-amino acid derivatives in racemic forms and
many methods for their preparation in enantiomerically pure
form have been reported in recent years. Intensive research has
focused on their transformations to heterocycles, peptides, or
other bioactive derivatives. The aim of the present review is to
survey the results on this exciting and intensive area of
development in the framework of cyclic β-amino acids.
The review begins with a presentation of the results achieved
in the past decade in the ﬁeld of carbocyclic derivatives.
Relevant synthetic routes will be given toward the preparation
of the largest family of these derivatives, i.e., the ﬁve- and six-
membered carbocyclic amino acids, followed by an account of
the smaller and then the larger ring analogs. The syntheses in
general will be described for the racemic substances, unless
asymmetric approches or enantioselective preparations are
presented, for which the product will be mentioned as enantiomeri-
cally pure; in the latter case, either absolute conf igurations or sign
of the optical rotations will be given. Since the functionalized
cyclic β-amino acids have attracted increasing attention in
Figure 1. β-Amino acid drugs.
Figure 2. Pharmacologically active β-amino acid derivatives.
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recent years, the most interesting procedures for the syntheses
of these derivatives will also be presented.
The second part of the review will be devoted to the
heterocyclic β-amino acids with carboxyl and extracyclic amino
functions attached to stereogenic C-centers of the ring, followed by
a structural organization depending on the nature of the
heteroatom and the ring size. Each part deals with the chemical
approaches toward the synthesis of these heterocyclic amino
acids, including the enantiomers, and their transformations to
other important bioactive substances, evaluated in terms of
applicability, usefulness, and limitations.
Besides the synthetic aspects, each section will provide
representative information on the biological importance and
applications of these interesting β-amino acids. The ﬁnal
concluding remarks will brieﬂy discuss the perspectives for
future research.
In view of the lack of any other comprehensive coverage of
the recent results on carbocyclic and heterocyclic β-amino
acids, a systematic review of their preparations and biological
eﬀects is likely to be of great interest to a wide range of
synthetic chemists and biochemists.
2. CARBOCYCLIC β-AMINO ACIDS
2.1. Syntheses of Five- or Six-Membered Carbocyclic
β-Amino Acids
The syntheses of cyclic β-amino acids have aroused
considerable interest in the past 2 decades as a result of their
presence in pharmacologically active compounds, other bio-
logically relevant products, and important peptides. The largest
and most important groups of cyclic amino acids are those with
ﬁve- or six-membered rings. One general mode of access to β-
aminocyclohexanecarboxylic acid is based on the trans-
formation of hexahydrophthalic anhydride (12) by amidation
and Hofmann degradation of the resulting amide (13) to the
corresponding β-aminocyclohexanecarboxylic acid 15.1a
In an alternative route, Curtius degradation of the half-ester
14 derived from anhydride 12 gives amino acid 15 (Scheme 1).
The above synthetic protocol has been applied eﬀectively for
the preparation of other related cyclic β-amino acids, such as
16, the trans counterpart of 15, 2-aminocyclohexenecarboxylic
acids 17 and 18, and the bicyclic di-endo-β-amino acids 19 and
20 (Figure 3).
Another rapid and simple procedure for the synthesis of ﬁve-
or six-membered cyclic β-amino acids consists of the ring-
opening transformation of bicyclic β-lactams (23) derived from
cycloalkenes (21a,b) by the cycloaddition of chlorosulfonyl
isocyanate (CSI) (Scheme 2). A full list of the abbreviations
used is to be found at the end of this review.
Bicyclic β-lactam ring-opening by hydrolysis or ethanolysis
has been extended toward the synthesis of enantiomerically
pure carbocyclic β-amino acids. Enzyme-catalyzed lactam ring-
opening of racemic azetidinone (23a,b) resulted in the
enantiomerically pure unreacted lactam and the corresponding
alicyclic cis-β-amino acid enantiomer (15a, 24c). The amino
acid enantiomers (15a, 24c) were prepared by an alternative
route: enzymatic hydrolysis of the racemic carbocyclic β-amino
esters (15b, 24d), during which the racemic ester aﬀorded the
optically pure β-amino acid and the unreacted β-amino ester
enantiomer. The latter procedure (see Scheme 2) allowed the
preparation of trans-β-amino acids. Both enzymatic resolution
methodologies furnish saturated alicyclic β-amino acid
enantiomers with diﬀerent ring sizes, and their counterparts
with a C−C double bond in the ring.1i−s
This lactam opening method has been eﬃciently used for the
preparation of a series of derivatives such as the β-amino-
cyclohexene (17) or cyclopentenecarboxylic (25) acids and for
the synthesis of bicyclic di-exo derivatives 26 or 27 (Figure
4).1a
Although the routes presented above for the preparation of
cyclic β-amino acids are eﬃcient and simple methods with high
Scheme 1. Syntheses of Carbocyclic β-Amino Acids via
Hofmann or Curtius Degradation
Figure 3. Several carbocyclic β-amino acids.
Scheme 2. Syntheses of Carbocyclic β-Amino Acids in
Racemic or Enantiomerically Pure Form via β-Lactam
Opening
Figure 4. Carbocyclic β-amino acids derived from β-lactams.
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overall yields and low costs that are applicable on a large scale,
they suﬀer from certain limitations: they aﬀord only racemates
or they are not applicable for the synthesis of a large variety of
substituted derivatives.
2.1.1. Carbocyclic β-Amino Acids from β-Keto Esters.
Carbocyclic β-keto esters, conveniently synthetized by the
Dieckmann condensation of acyclic diesters, are readily
available precursors for the preparation of ﬁve- or six-
membered cyclic β-amino acids. Cyclic β-amino carboxylates
are synthetized by the reduction of oximes or enamines formed
from the corresponding β-keto esters. Reductive amination of
cyclic β-keto esters is a suitable method for the synthesis of
carbocyclic β-amino acids in enantiomerically pure form.
Protected amino acid enantiomer 33 was prepared from ﬁve-
membered keto ester 28 by using (S)-α-methylbenzylamine as
chiral auxiliary (Scheme 3). Cyclic keto ester 28 was reacted
with (S)-α-methylbenzylamine to furnish enamine derivative 29
in high yield. Reduction of 29 with Na in i-PrOH led to trans-
amino alcohol 30, which was converted by removal of the chiral
auxiliary, N-Fmoc protection, and oxidation to trans-amino acid
enantiomer 33.6
An alternative simpliﬁed route has been described with the
same chiral auxiliary. The enamine resulting from the reaction
of keto ester 28 and (S)-α-methylbenzylamine was reduced
with NaCNBH3 to give trans-β-amino ester 31. Ester
hydrolysis, removal of the chiral auxiliary, and N-Fmoc
protection led to amino acid 33 (Scheme 3).6
Gellman et al. applied this method to prepare enantiomeri-
cally pure 4,4-disubstituted derivatives of trans-β-amino-
cyclopentanecarboxylic acids.7 The 4,4-disubstituted β-keto
esters were reacted with (R)-α-methylbenzylamine and the
resulting enamines were reduced with NaCNBH3. The
diastereomeric mixture of trans-amino esters was separated by
chromatography, followed by transformation to the corre-
sponding disubstituted cyclic β-amino acids 34−37 (Figure 5).
A general approach for the asymmetric synthesis of β-
aminocyclopentane-, cyclohexane-, cycloheptane-, and cyclo-
octanecarboxylic acids was reported by Tang et al.8 Their
method was based on the catalytic asymmetric hydrogenation
of enamines and, in contrast with the earlier strategies (see
Scheme 3), led to cis-β-aminocarboxylates. A Ru catalyst and a
chiral phosphine ligand were used to convert enamine 38 cis-
selectively to cis-aminocyclopentane or cyclohexane ester 39 in
99% ee (Scheme 4).
From cis-amino esters 39, the trans counterparts could be
easily synthetized by epimerization at C-1 with NaOEt.8 New
Rh complexes were used for the asymmetric hydrogenation of
β-acetamido dehydroamino acid derivatives by Wu et al.9a Yu et
al. have synthetized novel β-sulfonamidocyclopentanecarbox-
ylates by using Pd(OCOCF3)2/chiral diphosphine ligand
systems for the enantioselective hydrogenation of cyclic β-
arylsulfonamido acrylates.9b Developments relating to the large-
scale applicability of the asymmetric hydrogenation of
dehydroamino acids were reported by Enthaler et al.10 Novel
chiral phospine ligands were used in multi-10-g scale reactions,
and up to 94% ee was achieved.10
Enantiomerically pure β-(4-ﬂuorobenzyl)aminocyclo-
pentanecarboxylate (41) (Scheme 5) is a precursor of the
biologically interesting compound HCV NS5B,11 known as a
polymerase inhibitor. β-Keto ester transformation through the
enamine was applied for the synthesis of racemic 41. In this
case, reductive amination of 28 with 4-ﬂuorobenzylamine and
NaBH3CN furnished racemic cis-amino carboxylates 41,
together with minor amounts of trans derivative 42 (Scheme
5).
Resolution of racemic 41 with (S)-(+)-mandelic acid
aﬀorded the enantiomerically pure compounds.11
Reductive amination of β-keto esters is a suitable method
also for the synthesis of functionalized racemic carbocyclic β-
amino acids. An icofungipen (for the structure, see 2) analog 48
with an exocyclic methylene unit has been prepared in seven
steps from the benzyloxymethyl-containing keto ester 44 by
reductive amination (Scheme 6).2a
2.1.2. Carbocyclic β-Amino Acids by Metathesis.
Carbocyclic β-amino acids can be prepared from acyclic β-
amino acid derivatives by ring-closing metathesis. An important
advantage of this methodology is that it gives cyclic β-amino
acids whose oleﬁnic bond may be functionalized to yield novel
substituted derivatives. Chiral lithium amide addition to various
Scheme 3. Synthesis of a trans-β-Amino Acid from the
Corresponding β-Oxo Ester by Reductive Amination
Figure 5. Structures of several alicyclic trans-β-amino acids.
Scheme 4. Syntheses of Carbocyclic β-Amino Esters by Cis-
Selective Catalytic Reduction of Enamines
Scheme 5. Syntheses of cis- and trans-β-Amino Esters by
Reduction of Enamines with NaBH3OAc
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unsaturated acyclic esters aﬀorded acyclic dieno amino esters
49 and 50 (for the conjugate addition to α,β-unsaturated esters,
see also section 2.1.3), generating two stereogenic centers.
These unsaturated amino esters were transformed by ring-
closing metathesis with a Ru alkylidene catalyst to the
corresponding β-aminocycloalkene esters 51 and 52 (Scheme
7). The conﬁguration of the chiral centers in 49 and 50
determined the trans stereochemistry in the carbocyclic
products 51 and 52.12a
Unsaturated cyclic β-amino acid enantiomers were synthe-
tized from enantiomerically pure α-amino acids via a ring
closure metathesis as key step.
The transformation of (S)-methionine or (R)-allylglycine
involving allylation and the Arndt−Eistert reaction resulted in
amino ester 53 or 55, which under ring-closing metathesis
conditions furnished the corresponding ﬁve- or six-membered
cyclic β-amino ester enantiomers (Scheme 8).12b
β-Lactams can be easily transformed to the corresponding β-
amino acids by lactam ring-opening. Dienes possessing a β-
lactam framework (57) were converted through acyclic β-
amino acid derivatives 58 by intramolecular ring-closing
metathesis to aﬀord unsaturated carbocyclic trans-β-amino
esters (59). The conﬁgurations of the stereocenters in the
starting lactam 57 were not aﬀected during the process, which
resulted in ﬁve- or six-membered trans-amino acid enantiomers
60 after removal of the chiral auxiliary (Scheme 9).13
The synthetic protocol based on metathesis oﬀered an
opportunity for the preparation of functionalized carbocyclic β-
amino acids. A general method for the synthesis of diﬂuorinated
Scheme 6. Synthesis of Exomethylenic β-Aminocyclopentanecarboxylic Acid by Reductive Amination
Scheme 7. Syntheses of trans-β-Aminocycloalkenecarboxylates from α,β-Unsaturated Esters
Scheme 8. Syntheses of trans-β-
Aminocycloalkenecarboxylates from S-Methionine and R-
Allylglycine
Scheme 9. Syntheses of trans-β-Aminocyloalkanecarboxylic
Acids from Diene β-Lactams
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β-aminocyclopentane-, cyclohexane-, and cycloheptanecarbox-
ylic acids via a cross-metathesis reaction as key step was
developed by Fustero et al.14 The cross-metathesis of geminal
diﬂuorinated imidoyl chlorides (61) with ethyl acrylate to give
62 was followed by saturation of the oleﬁnic bond to
diﬂuorinated imino ester 63, intramolecular base-mediated
ring closure of which furnished the corresponding diﬂuorinated
cyclic β-amino ester 64 (Scheme 10). Catalytic hydrogenation
of 64 resulted in racemic diﬂuorinated ﬁve- or six-membered
cis-β-aminocycloalkanecarboxylates (66).
The above synthetic strategy was extended to the preparation
of enantiopure diﬂuorinated β-amino ester. This was
accomplished by using (−)-8-phenylmenthol as chiral auxiliary.
LDA-mediated ring closure of the phenylmenthyl ester (the
cross-metathesis product) and subsequent hydrogenation gave
the corresponding enantiomerically pure cyclic cis-amino
ester.14a
The cross-metathesis of imidoyl chlorides with unsaturated
esters, such as pent-4-enoate or but-3-enoates, was later
extended by the same research group to the preparation of
cyclic diﬂuorinated β-amino acid enantiomers with various ring
sizes.14b
A method relatively similar to the above-described enolate
addition to imidoyl chlorides involved the intramolecular
cyclization of imines and ester enolates, when benzo-fused
cispentacins were synthetized.15
The chiral imine 68, derived from 67, underwent intra-
molecular addition in the presence of various bases. The
reaction with LiHMDS (lithium hexamethyldisilylamide) or
KHMDS at room temperature resulted in β-lactam stereo-
isomers 69 and 70 and benzofused transpentacin derivative 71
in a ratio of 49:18:33 or 30:31:39 (Scheme 11). When the
addition was carried out with NaHMDS, only the lactams were
detected in a ratio of 77:23. Moreover, at −40 °C in the
presence of a crown ether catalyst, excellent selectivity (69:70
99:1) was attained. Compound 69 was readily transformed by
chiral auxiliary removal and lactam opening to the correspond-
ing enantiomerically pure benzo-fused cispentacin 72 (Scheme
11).
This ring-closing method was also applied for the preparation
of dimethyl-substituted cispentacin. Imino ester 73, obtained
from 4,4-dimethylcyclohexanone, readily aﬀorded β-lactam 74
with high diastereoselectivity (dr 97:3) by intramolecular
nucleophilic addition (Scheme 12).15
A recent method involving ring-closing metathesis was
developed by Davis et al. Addition of unsaturated carboxylic
acid derivative 76 to p-toluenesulﬁnylimine 75 with a C−C
Scheme 10. Syntheses of Diﬂuorinated β-Aminocycloalkanecarboxylates from Fluorinated Imidoyl Chlorides
Scheme 11. Synthesis of Benzo-Fused Cispentacin from Imino Esters
Scheme 12. Synthesis of Bicyclic β-Lactam from Imino
Esters
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double bond furnished syn (dr > 99:1) dieno amino carboxylic
acid derivative 77, whose ring-closing metathesis aﬀorded the
corresponding ﬁve- or six-membered carbocyclic cis-β-amino
acid derivative (Scheme 13). The relative conﬁguration of the
chiral C-centers in 77, resulting from the syn-selective addition
between 75 and 76, determined the cis stereochemistry in the
carbocyclic product 78.16
2.1.3. Carbocyclic β-Amino Acids by Amino Group
Conjugate Addition. α,β-Unsaturated carbocyclic acid
derivatives are excellent starting materials for the synthesis of
cyclic β-amino acids.17a
Stereoselective conjugate addition of an amine nucleophile
derivative to an α,β-unsaturated carboxylate is an eﬃcient
strategy for access to ﬁve- or six-membered cyclic β-amino
acids. Chiral lithium amides such as (S)-80 have been used as
chiral ammonia equivalents for this purpose. Addition of (S)-80
to ester 79 led completely stereoselectively to cis-amino ester
derivative 81, which, after removal of the chiral auxiliary by
hydrogenolysis, provided cis-2-aminocyclopentanecarboxylic
acid enantiomer (82) in 98% ee (Scheme 14).17b,104
An important advantage of this strategy is its ready
applicability for the preparation of alkyl-substituted analogs of
cispentacin in enantiomerically pure form. Davies et al. further
extended this methodology.
tert-Butyl 3-methylcyclopentenecarboxylate was used as
starting material for the preparation of 3-methyl-substituted
cispentacin enantiomers (83−85; Figure 6) in 98% ee.18
By using the conjugate addition technique, the same research
group also synthetized 5-alkyl-substituted cispentacins. Addi-
tion of chiral amide (S)-80 to 5-isopropyl-, 5-phenyl-, and 5-
tert-butylcyclopentenecarboxylates led with a high degree of
stereoselectivity to the major derivatives with the amine trans to
the 5-alkyl group. Removal of the chiral auxiliary and
subsequent ester hydrolysis aﬀorded 5-substituted cispentacins
in 98% ee.19
Conjugate addition proved to be a suitable method also for
the synthesis of various other functionalized cyclic β-amino acid
derivatives. Starting from diene 86, 2-amino-5-carboxymethyl-
cyclopentanecarboxylate stereoisomers were synthetized by the
addition of lithium amide (R)-80. Addition products 87 and 88
resulting from the reaction of 86 and (R)-80 were separated by
column chromatography.
Removal of the chiral auxiliary and subsequent ester
hydrolysis aﬀorded optically active amino diacids 89 and 90
with ee up to 99% (Scheme 15).20
This functionalization strategy was extended to the
preparation of cyclohexane analogs. Starting from a diene
dicarboxylate, conjugate addition followed by ring closure by
using chiral lithium amide (S)-80 proceeded with high
diastereoselectivity to give the corresponding aminocyclohex-
anecarboxylates.21
Hydroxy-functionalized cyclopentane or cyclohexane β-
amino acids were prepared by applying the conjugate
addition−ring closure procedure. Unsaturated formyl carbox-
ylates (91) served as suitable starting materials for this purpose.
Similarly to the transformations presented above, enantiomeri-
cally pure 5- and 6-hydroxylated cyclopentane- and cyclo-
hexanecarboxylic acids (93) were obtained (Scheme 16).21
The parallel kinetic resolution of substituted unsaturated
esters is an interesting application of chiral amide conjugate
addition. Addition of a 1:1 mixture of a pseudoenantiomeric
mixture of (S)-80 and (R)-98 (Figure 7) to racemic 5-
tris(phenylthio)methylcyclopent-1-enecarboxylate (95, derived
from 94) provided tris(phenylthio)amino ester derivatives 96
and 97 with de higher than 98% (Scheme 17).
After chromatographic separation, 96 and 97 were subjected
to Raney Ni reductive desulfurization to furnish 5-methyl-
substituted derivatives. Hydrogenolysis and ester hydrolysis
gave (1R,2S,5S)- and (1S,2R,5R)-5-methylcispentacin (99 and
100) in 98% ee (Figure 8; for 5-alkyl-substituted cispentacins,
see also ref 19).22
The parallel kinetic resolution strategy based on conjugate
addition was eﬃciently used for the preparation of 6-methyl-
substituted β-aminocyclohexanecarboxylic acid enantiomers23
and 3-alkyl-substituted cispentacin enantiomers.24
Chiral lithium amide (80) addition to unsaturated cyclic
esters (79; Scheme 14) provided cis-β-amino ester 81, while the
N-protected transpentacin could be easily prepared by
epimerization of 81 at C-1 with base. On treatment with t-
BuOK, 81 led to the corresponding trans derivative 101.
Scheme 13. Syntheses of cis-β-Aminocycloalkanecarboxylates from Unsaturated Sulﬁnimines and Weinreb Amide
Scheme 14. Synthesis of Cispentacin from α,β-Unsaturated
Esters and Lithium Amides
Figure 6. Structures of methyl-substituted cispentacin and trans-
pentacin synthetized by lithium amide conjugate addition.
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Removal of the chiral auxiliary, N-protection, and ester
hydrolysis gave transpentacin enantiomer 102 (Scheme 18).25
The double Michael conjugate addition outlined in Scheme
15 was eﬃciently further developed by Ozeki et al. for the
synthesis of functionalized β-aminocycloalkanecarboxylates
with multiple chiral centers by the addition of diﬀerent
aldehydes. Analogously to the process presented in Scheme
15, addition of amino alcohol derivative 103 as chiral auxiliary
to diene 104 gave the corresponding amino dicarboxylate 106.
However, in the presence of an aldehyde, the reaction led not
only to 106 but also to 105, formed in a yield of 6−45% by a
Scheme 15. Syntheses of Aminocyclopentanedicarboxylic Acids by Lithium Amide Addition to Diene Carboxylates
Scheme 16. Syntheses of Hydroxylated β-Aminocycloalkanecarboxylic Acids by Lithium Amide Addition to Unsaturated Oxo
Esters
Figure 7. Structures of chiral lithium amides.
Scheme 17. Addition of Lithium Amides to Phenylthio α,β-Unsaturated Esters
Figure 8. Methyl-substituted cispentacins synthetized by chiral lithium
amide conjugate addition.
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tandem Michael−aldol reaction. After chromatographic sepa-
ration, removal of the chiral auxiliary in 105 resulted in the
enantiomerically pure, functionalized β-amino acid derivative
107 (Scheme 19).26
2.1.4. Carbocyclic β-Amino Acids by Cycloaddition.
Diels−Alder cycloaddition is a widely used as an eﬃcient
method for the construction of a cyclic compound with new
stereogenic centers and can also be applied for the synthesis of
cyclic β-amino acids. Addition of butadienecarbamate 108 to
acrylate 109 provided a mixture of two cycloadducts, cis- and
trans-2-amino-3-cyclohexenecarboxylates 110 and 111, in a
ratio of 4:1.
Diastereoisomers 110 and 111 were separated by chroma-
tography, and treatment with trimethyliodosilane (TMSI)
furnished racemic cis- and trans-cyclohexene amino acids 112
and 113 (Scheme 20).27
(4 + 2)-Cycloaddition has been eﬃciently utilized for the
preparation of enantiomerically pure β-amino acids. Unsatu-
rated nitro ester 114 bearing a pyrrolidinone moiety as chiral
auxiliary was subjected to cycloaddition with 1,3-cyclo-
hexadiene to furnish bicyclic β-nitro ester 115. Nitro group
reduction, followed by removal of the chiral auxiliary by
hydrolysis, gave enantiopure amino acid 117 (Scheme 21).28
Cycloaddition is not only a powerful technique for the ring
construction but may also be used for the functionalization of
molecules. In order to prepare cyclic β-amino acids, both the
carboxylic and amino groups can be introduced onto the
skeleton of a cycloalkane by 1,3-dipolar nitrone cycloaddition.
A nitrone generated from aldehyde 118 and chiral (R)-N-
hydroxyphenylglycinol 119 by intramolecular addition in the
presence of MgBr2 and i-PrOH furnished isoxazolidine 120
with high cis diastereoselectivity (diastereoisomeric ratio 96:4)
(Scheme 22). Cycloadduct 120 was readily converted to
cispentacin 121.29
Nitrones generated from the enantiomerically pure unsatu-
rated dithioacetal 122 were also eﬃciently used for the
synthesis of cyclic β-amino acid enantiomers. Isoxazolidine
123 was formed as a single diastereoisomer (Scheme 23).
Reductive cleavage of the N−O bond and removal of the
dithioacetal moiety followed by debenzylation resulted in
(1R,2S)-cispentacin (1).30a
Intramolecular nitrone cycloaddition was the key step in the
synthesis of cyclopentanecarboxylic acid via an intermediate
isoxazolidine derivative. Enantiomerically pure unsaturated
aldehyde 125 was readily transformed with N-benzylhydroxyl-
amine through the corresponding nitrone 126 to isoxazolidine
127. Reductive heterocycle cleavage followed by N-Boc
protection gave amino alcohol 129 (Scheme 24).
Under oxidative conditions, 129 was transformed to a
phenyl-substituted enantiopure cyclopentane β-amino acid
(130).30b
2.1.5. Carbocyclic β-Amino Acids by Desymmetriza-
tion of meso-Anhydrides. In general, an asymmetric
synthesis suﬀers from limitations with regard to the possibility
of the large-scale preparation of the required enantiomerically
pure substances. Desymmetrization of the readily available
meso-anhydrides allows large-scale work. Mittendorf et al.
prepared amino acid 2 (icofungipen) in high enantiomeric
excess by using the desymmetrization procedure.31
Alcoholysis of anhydride 132 (derived from acid 131) with
cinnamyl alcohol in the presence of a stoichiometric amount of
quinine furnished hemiester 133. Curtius rearrangement
followed by Pd-catalyzed ester and amine deprotection aﬀorded
amino acid enantiomer 2 (Scheme 25).
The general applicability of desymmetrization was demon-
strated by Bolm et al. Desymmetrization of easily accessible
meso-anhydrides by cinchona-mediated ring-opening with
benzyl alcohol aﬀorded diﬀerent hemiesters with high
enantioselectivities. These hemiesters were transformed to
enantiomerically pure cyclopentane, norbornane, or norbor-
nene β-amino acids.32
Four enantiomerically pure endo isomers of icofungipen (2)
were prepared by Hamersak et al. by quinine-mediated
desymmetrization of the corresponding racemic anhydride,
followed by a Curtius reaction.33
Scheme 18. Synthesis of Z-Protected Transpentacin by
Chiral Lithium Amide Conjugate Addition
Scheme 19. Synthesis of Functionalized tert-Butyl β-
Aminocyclohexanecarboxylate by Conjugate Addition of
Chiral Amine to Unsaturated Diesters
Scheme 20. Syntheses of Racemic β-
Aminocyclohexenecarboxylic Acids by Diels−Alder
Cycloaddition
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Anhydride 132 was isomerized to its endo derivative 135,
which was next subjected to alcoholysis in the presence of
quinine, giving hemiesters 136 and 137 in a ratio of 3:7
(Scheme 26). These esters could not be separated, but their
conversion by the Curtius rearrangement aﬀorded the separable
amino ester stereoisomers 138 and 139. Deprotection of the
ester and amino functions resulted in β-amino acid enantiomers
140 and 141 in 99% and 96% ee. Base-mediated isomerization
of 139 furnished novel stereoisomer 142 in 96% ee (Scheme
26).
The fourth stereoisomer (144) was obtained by exo−endo
isomerization of the enantiomerically pure icofungipen (2) with
trimethylsilyl choride (TMSCl) and NaI (Scheme 27).33
2.1.6. Carbocyclic β-Amino Acids from Natural
Sources. An eﬃcient and convenient means of access to
optically pure carbocyclic β-amino acids is the transformation
Scheme 21. Synthesis of Bicyclic β-Amino Acid Enantiomerically Pure 117 through Cycloaddition of an Unsaturated Nitro Ester
and 1,3-Cyclohexadiene
Scheme 22. Synthesis of Cispentacin from a Bicyclic
Isoxazolidine
Scheme 23. Synthesis of Cispentacin Enantiomer 1 from an
Enantiomerically Pure Ketene Dithioacetal
Scheme 24. Synthesis of a Phenyl-Substituted Cispentacin Derivative
Scheme 25. Synthesis of Icofungipen
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of readily available chiral monoterpenes. The method widely
used for the synthesis of bicyclic β-lactams by CSI addition is
the key step, involving the C−C double bond transformation of
these natural sources for the synthesis of monoterpene-based β-
amino acids. By starting from diﬀerent monoterpenes, a series
of cyclic β-amino acids were synthetized. For example,
treatment of α-pinene (145) with CSI led regio- and
stereoselectively to β-lactam 146, the N-Boc protection and
lactam opening of which resulted in carbocyclic β-amino acid
enantiomer 148 (Scheme 28).34
Another monoterpene isomer of 145, δ-pinene, also
underwent CSI addition regio- and stereoselectively to give
the corresponding β-lactam 149, which was next converted to
the δ-pinene-based β-amino acid 150 (Figure 9).35
Through application of a similar strategy, enantiomerically
pure β-amino acid 152 was easily prepared from the readily
available (+)-3-carene. The corresponding β-lactam 151 was
produced regio- and stereoselectively by the addition of CSI,
and subsequent N-Boc protection followed by lactam opening
furnished optically active 152 (Figure 10).36
In contrast with the above CSI additions to various
monoterpenes, the addition to (+)-2-carene (153) was not
regioselective and gave β-lactam isomers 154 and 155 in a ratio
of 3:2 (Scheme 29). After separation by crystallization, these β-
lactams were converted to the corresponding amino acids 156
and 157.37
Another readily accessible starting material for the
preparation of carbocyclic β-amino acid is chiral (−)-apopi-
Scheme 26. Syntheses of Icofungipen Isomers from a meso-Anhydride
Scheme 27. Synthesis of an Icofungipen Analog by Isomerization of Icofungipen
Scheme 28. Chiral β-Amino Acids Derived from α-Pinene
Figure 9. Structures of a α-pinene-derived β-lactam and β-amino acid.
Figure 10. Structures of a β-lactam and a β-amino acid derived from
(+)-3-carene.
Scheme 29. Syntheses of β-Amino Acids from (+)-2-Carene
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nene, prepared from commercially available (−)-myrtenal.
Regio- and stereoselective CSI addition followed by lactam
opening aﬀorded enantiomerically pure lactam and amino acid
158 and 159 (Figure 11).38
As a convenient chiral natural source, (+)-myrtenal (160)
was also eﬃciently used for the synthesis of cyclic β-amino acid
enantiomers. Michael lithium amide trans-selective addition
(for conjugate amine addition, see section 2.1.3) to ester 161
(derived from 160) gave 162, the debenzylation and ester
hydrolysis of which led to a novel monoterpene-based trans-β-
amino acid (163) in enantiomerically pure form (Scheme
30).39
2.1.7. Miscellaneous. The Strecker reaction is a well-
known general approach for the synthesis of α-amino acids.
Enantiomerically pure carbocyclic α,β-diamino acid derivatives
could be prepared with this method by reacting (R)-α-
methylbenzylamine with amino ketone 164. Cyanide addition
to the resulting imine 165 led to a mixture of diastereoisomers
166, which were separated by column chromatography after
nitrile hydrolyis. Through removal of the chiral auxiliary and
amide hydrolysis, the amide stereoisomers obtained (167 and
168) aﬀorded the corresponding α,β-diaminocyclohexanecar-
boxylic acids 169 and 170 with an ee of 99% (Scheme 31).40
The syntheses of all four enantiomers of cis- and trans-2-
aminocyclohexanecarboxylic acids were achieved from enantio-
merically pure quinazolinone 171. Diastereoselective hydro-
genation of 171 with PtO2 provided octahydroquinazolinone
diastereoisomers 172, 173, and 174 in a ratio of 6:3:1. Cis-
annelated derivatives 172 and 173 could be isomerized with
KOt-Bu to give the corresponding trans-fused derivatives 174
and 175. Subsequently, all four octahydroquinazolinones
(172−175) were converted by ring-opening with HCl,
followed by ion-exchange chromatography, to furnish the
corresponding two cis- and two trans-2-aminocyclohexanecar-
boxylic acid enantiomers (Scheme 32).41
Carbocyclic β-amino acids have also been synthetized
through the radical addition−cyclization of sulfanilic com-
pounds. Cyclization was achieved from oximes or hydrazones
with thiophenol and AIBN as radical initiator, furnishing
diastereomeric mixtures of 176 and 177 and of 178 and 179 in
ratios of 3.3:1 and 2:1, respectively. The diastereomeric
mixtures 176, 177 and 178, 179 were next transformed to
the Boc-protected amine diastereomers 180, which were
converted through sulfoxide 181 by pyrolysis to the cyclic
exomethylene derivative 182. Hydroboration of the C−C
double bond gave cis-amino alcohol 183 with high regio- and
diastereoselectivity. In the last step, oxidation of 183 led to the
Boc-protected cispentacin 184 (Scheme 33).42 Via this
procedure, various carbocyclic β-amino acids and heterocyclic
analogs of cispentacin were synthetized, these examples
revealing the great advantage of this method.
A relatively new approach to transpentacin was presented by
Joosten et al. A highly trans-diastereoselective tandem hydro-
zirconation and Lewis acid-promoted cyclization of oxazoli-
dines with an unsaturated side chain (185) furnished trans-
Figure 11. Structures of a β-lactam and a β-amino acid derived from
(−)-apopinene.
Scheme 30. Synthesis of a β-Amino Acid from (+)-Myrtenal
Scheme 31. Syntheses of α,β-Diaminocyclohexanecarboxylic Acids by the Strecker Reaction of Imines
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cyclopentane amino alcohol 186, which was next converted by
debenzylation, oxidative cleavage, and Boc protection to amino
alcohol 187. Removal of the O-protecting group, alcohol
oxidation with NaIO4 with a catalytic amount of RuO2, and
esteriﬁcation aﬀorded transpentacin derivative 188 (Scheme
34).43
2.2. Syntheses of Small-Ring Carbocyclic β-Amino Acids
As conformationally rigid compounds, β-aminocyclopropane-
carboxylic acids are considered very attractive building elements
for the synthesis of novel peptides. However, in consequence of
their instability and high reactivity, they have only limited
usage. In general, only the protected derivatives exhibit
stability.44 The most common synthesis of β-aminocyclopro-
panecarboxylic acid derivatives involves the addition of a
carbene analog such as diazomethane or a diazocarboxylate to a
C−C double bond.44 Another method consists of the
intramolecular ring closure (Michael-induced ring closure) of
β-amino-γ- iodocarboxylates to cyclopropane amino esters.45
Carboxylate-substituted cyclopropanes may be constructed by
the reaction of α-bromocarboxylate 189 with methyl acrylate.
This reaction provided diastereomers 190 and 191 in a ratio of
4:1. After hydrolysis and treatment with AcCl, diester 190
furnished anhydride 193, which was then converted by
esteriﬁcation and Curtius rearrangement to the Boc-protected
β-aminocyclopropane ester 195 (Scheme 35).45a
Another easy route to β-aminocyclopropanecarboxylates
starts from 2-bromocyclopropanecarboxylic ester 196 through
a bromide secondary amide exchange by substitution in the
presence of base and crown ether catalyst to give amino acid
derivative 197 (Scheme 36).46
Although the building block potential in peptide synthesis of
β-aminocyclobutanecarboxylic acids as conformationally rigid
compounds is known, only a few such syntheses have been
reported.47
Aitken et al. developed an eﬃcient procedure for the
synthesis of (1S,2R)- and (1R,2S)-β-aminocyclobutanecarbox-
ylic acids 203 and 204 by using a chiral uracil mimic 198. The
Scheme 32. Precursors for Cyclohexane β-Amino Acids from Benzopyrimidinones
Scheme 33. Synthesis of Cispentacin by Radical Cyclization
of Amino Sulfanilic Compounds
Scheme 34. Synthesis of Methyl trans-β-
Aminocyclohexanecarboxylate by Hydrozirconization of
Unsaturated Oxazolidines
Scheme 35. Syntheses of Methyl-Substituted Cyclopropane
β-Amino Acids
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photocycloaddition of ethylene to 198 aﬀorded a mixture of cis-
annelated cycloadduct diastereomers 199 and 200. This
mixture could be separated by chromatography; subsequent
transformations, ﬁnally involving heterocyclic ring hydrolysis,
led to cyclobutane amino acid enantiomers 203 and 204 in
overall yields of 33% and 20%, with an ee value of >97%
(Scheme 37).48
Starting from the chiral uracil derivative, the same research
group prepared all four stereoisomers of 2-aminocyclobutane-
carboxylic acid enantiomers, by using a similar synthetic
strategy involving photochemical (2 + 2)-cycloaddition and
isomerization of the cis- to the trans-β-amino acid.49 The
incorporation of cyclobutane cis-β-amino acids into peptides
has also been reported.50 This technique of cycloaddition of an
oleﬁnic bond into the uracil derivative has been successfully
applied for the preparation of hydroxymethylated β-amino-
cyclobutanecarboxylic acid stereoisomers 205 and 206 (Figure
12).51
Ortuno et al. synthetized enantiomers of cis-β-amino-
cyclobutanecarboxylic acids from the enantiomerically pure
hemiester 207, which was prepared by desymmetrization of
meso-cyclobutane-1,2-dicarboxylic acid methyl ester. The
synthetic protocol involved Curtius rearrangements of
azidocarbonyl esters as the key step (Scheme 38). The opposite
enantiomer of 204 was also prepared from hemiester 207.52
A novel approach for the preparation of cis- and trans-β-
aminocyclobutanecarboxylic acid enantiomers used (R)-α-
methylbenzylamine as chiral auxiliary, which on reaction with
cis-amino acid 210 aﬀorded diastereoisomers 211 and 212 in a
ratio of 1:1. These two compounds were separated by
chromatography, and then, after removal of the chiral auxiliary,
the resulting amides were converted to cis-β-aminocyclobuta-
necarboxylic acid enantiomers 203 and 204. On treatment with
NaOH, the amide intermediates underwent epimerization to
yield the corresponding trans-β-amino acid enantiomers 213
and 214 (Scheme 39).53
As a general method for the synthesis of cyclic α,β-
diaminocarboxylic acids (Scheme 28), the Strecker synthesis
was eﬃciently used for the preparation of this type of
compound containing a cyclobutane ring. For this purpose,
aminocyclobutanone was ﬁrst reacted with (S)-α-methylbenzyl-
amine to give two of the four possible imine diastereoisomers
(E/Z), which were transformed as a mixture without isolation
on treatment with NaCN to give 216 and 217. After separation
by chromatography, these derivatives were converted by chiral
auxiliary removal and nitrile hydrolysis to cyclobutane amino
acid enantiomers 218 and 219 (Scheme 40).54
The desymmetrization protocol of meso-anhydrides devel-
oped by Bolm et al. (section 2.1.5) also permitted the synthesis
of enantiomerically pure cyclobutane β-amino acids.32
2.3. Syntheses of Carbocyclic β-Amino Acids with Larger
Ring Systems
Although less abundant than the ﬁve- or six-membered
derivatives, the larger-ring analogs of carbocyclic β-amino
acids may be accessed by using several synthetic methods.
Scheme 36. Syntheses of Racemic Cyclopropane β-Amino
Acids from Bromocyclopropanecarboxylic Esters
Scheme 37. Syntheses of Cyclobutane β-Amino Acid
Enantiomers from a Chiral Uracil Derivative
Figure 12. Hydroxylated cyclobutane β-amino acid stereoisomers.
Scheme 38. Synthesis of cis-Cyclobutane β-Amino Acid via a
Curtius Rearrangement
Scheme 39. Preparation of Enantiomerically Pure
Cyclobutane β-Amino Acids by Resolution of the Racemic
Compound
Chemical Reviews Review
dx.doi.org/10.1021/cr300454h | Chem. Rev. 2014, 114, 1116−11691129
Although a good number of generally applicable and eﬃcient
methods are available for the synthesis of ﬁve- and six-
membered cyclic trans-β-amino acids, there are fewer examples
of the synthesis of analogs with larger ring systems, such as
cycloheptane or cyclooctane derivatives.
A general procedure for the preparation of carbocyclic β-
amino acids containing a larger than six-membered ring system
is analogous to that for the ﬁve- or six-membered counterparts.
It consists of the cycloaddition of CSI to carbocycles with one
or two C−C double bonds in the ring. The addition of CSI to
cyclooctene or 1,5-cyclooctadiene, for example, proceeded via
the corresponding β-lactams to yield the racemic eight-
membered cis-β-amino acids 220 and 221 (Figure 13).1a
Analogously, 12-membered counterparts have been synthe-
tized by using a similar protocol.55
Another method for the preparation of cycloheptane β-
amino acid is based on catalytic asymmetric hydrogenation of
the corresponding cyclic enamines (e.g., 222), aﬀording cis-β-
aminocarboxylate 223 (ee 80%). A Ru catalyst and a chiral
phosphine ligand were used in this reaction (Scheme 41).8
Access to seven-membered cyclic β-amino acid derivatives
was achieved by ring-closing metathesis (for ﬁve- or six-
membered analogs, see Scheme 7) of dioleﬁnic intermediate
224 (derived from α,β-unsaturated esters and chiral amides),
the result being the corresponding trans-β-amino cycloheptene
ester 225, in which the oleﬁnic bond is at a two C-atom
distance from to the amine moiety (Scheme 42).12a
Ring-closing metathesis of 226 (derived from optically pure
serine) was the key step for the synthesis of trans-β-
aminocycloheptene ester enantiomer 227, in which the C−C
double bond is at a three C-atom distance from the carbamate
group (Scheme 43).12b
A diﬂuorinated cycloheptane cis-β-amino ester (230) was
prepared from the cross-metathesis product 229 in several steps
by C−C double bond saturation and ring closure via base-
promoted Cl displacement as the key step (Scheme 44; see also
Scheme 10).14
Lithium amide conjugate addition to α,β-unsaturated esters
(see section 2.1.3) was eﬃciently extended for the synthesis of
cyclic cis-β-amino acids with larger ring systems.
Thus, chiral lithium amide addition to 231 gave 232, which
after deprotection led to the cyclooctane cyclic β-amino acid
enantiomer 220 (Scheme 45), while from the diene derivative
the corresponding cyclooctene β-amino ester was analogously
obtained.56
A simple synthesis of seven- or eight-membered trans-β-
amino acids from the readily available cis-2-hydroxycycloalka-
necarboxylates (233) involves substitution of the hydroxy
group with azide by inversion via the tosylates (234), which
results in trans-2-azidocarboxylates 235. Azide reduction
followed by ester hydrolysis aﬀorded the corresponding
cycloheptane and cyclooctane trans-β-amino acids 237a and
237b (Scheme 46). The method was also extended to the
synthesis of the enantiomerically pure materials, starting from
the enantiomerically pure esters (233) obtained by enzymatic
resolution of the racemates.57
Scheme 40. Syntheses of Cyclobutane α,β-Diamino Acids
Figure 13. Cyclooctane and cyclooctene β-amino acids.
Scheme 41. Synthesis of a cis-Cycloheptane β-Amino Ester
from the Corresponding Enamine
Scheme 42. Synthesis of a Cycloheptene β-Amino Ester by
Metathesis
Scheme 43. Synthesis of a Cycloheptene β-Amino Ester from
S-Serine
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2.4. Synthesis of Functionalized Carbocyclic β-Amino Acids
Highly functionalized carbocyclic amino acids have aroused
considerable interest in the past 10 years. Introduction of a
functional group (e.g., hydroxy, azido, amino, ﬂuoro) into the
carbocycle of an amino acid may have a major inﬂuence on its
biological activity and on the pharmacological properties of the
subsequent peptides.
Some representative compounds, such as oryzoxymycin
(238),1 peramivir (239),58 or Tamiﬂu (240),59 exhibit strong
antiviral, antifungal, or antibacterial activities (Figure 14).
Modiﬁed derivatives and other multisubstituted cyclohexane
amino acids60 have recently been the focus of interest in
synthetic and medicinal chemistry in view of their enormous
pharmacological potential.
An increasing number of highly functionalized carbocyclic β-
amino acids derivatives (analogs of Tamiﬂu) have been
synthetized and investigated as potential antiviral agents in
recent years (Figure 15).61
Whereas numerous highly substituted derivatives of cyclic α-
or γ-amino acids with interesting biological activities have been
synthetized and investigated, the functionalized β-amino acids
have received less attention. However, due to their pharmaco-
logical potential, an increasing number of publications are now
being devoted to these carbocyclic β-amino acids. The aim of
this section is to summarize the most relevant synthetic
techniques for access to these compounds.
2.4.1. Syntheses of Functionalized Cyclic β-Amino
Acids by C−C Double Bond Functionalization. One main
route to multisubstituted carbocyclic β-amino acids is based on
the selective functionalization of their ring C−C double bond
(Figures 3 and 4 contain several examples of starting materials).
The most important methods involving these strategies are
presented brieﬂy in this section.
2.4.1.1. Functionalization via Selective Iodolactonization.
A method widely used for the regio- and stereoselective
functionalization of carbocyclic β-amino acids consists of the
iodolactonization of N-Boc-protected amino acids. For
example, on treatment with KI/I2 in the presence of
NaHCO3, cis-2-aminocyclohexenecarboxylic acid 245 gave
iodolactone 246 regio- and stereoselectively. Reductive
deiodination with nBu3SnH, followed by lactone ring-opening
and N-deprotection under acid catalysis, selectively furnished
all-cis-5-hydroxylated β-aminocylohexanecarboxylic acid 248
(Scheme 47).62
Scheme 44. Synthesis of a Diﬂuorinated Cycloheptane β-Amino Ester
Scheme 45. Synthesis of Enantiopure cis-Cyclooctane β-Amino Acid by Conjugate Addition to the Corresponding Unsaturated
Ester
Scheme 46. Syntheses of trans-Cyclooctane and
Cycloheptane β-Amino Acids
Figure 14. Some bioactive highly functionalized cyclic amino acids.
Figure 15. Structures of β-amino acid-modiﬁed Tamiﬂu analogs.
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This method allowed the preparation of other regio- and
stereoisomers of a series of other hydroxylated alicyclic β-amino
acids.63
The iodolactonization procedure was easily applicable for the
synthesis of hydroxylated carbocyclic β-amino esters with a C−
C double bond in their ring. For example, iodolactone 246,
obtained from 245 by treatment with DBU as base, was
transformed by HI elimination to unsaturated lactone 249,
which in the presence of NaOEt in EtOH at 0 °C gave all-cis-
cyclohexene β-amino ester 250 (Scheme 48).64
Starting from 1,4-cyclohexadiene- or 1,3-cyclohexadiene-
derived bicyclic lactams, the above methodology based on
iodolactonization, HI elimination, and subsequent lactone ring-
opening was successfully used for the synthesis of other
hydroxylated β-aminocyclohexenecarboxylates (Figure 16).64,65
The ring C−C double bond of hydroxylated cyclic β-amino
acids oﬀers a possibility for further selective functionalizations,
leading to the synthesis of diﬀerent highly functionalized
bioactive compounds. Thus, all-cis-methyl 5-hydroxy-2-amino-
cyclohexenecarboxylate was used as a precursor in the synthesis
of the antibiotic Fortamycine.66
The hydroxy function selectively attached to the carbocycle
of a β-amino acid may also be transformed to a series of other
functional groups. Hydroxylated amino ester 255 was easily
converted via mesylation, followed by mesyloxy group
substitution with azide and reduction, to orthogonally
protected diaminocyclohexanecarboxylate stereoisomers 257
and 258 (Scheme 49).67
Stereo- and regioselective hydroxylation and hydroxy−azide
interconversion were the key steps for the synthesis of other
orthogonally protected diaminocyclohexanecarboxylic acid
stereoisomers (259 and 260) (Figure 17).68
Because of the considerable importance of ﬂuorinated
organic molecules, and especially of ﬂuorinated amino acids,
in the area of medicinal chemistry and drug research, much
eﬀort has been devoted to the synthesis of ﬂuorinated cyclic β-
amino acids. By using organic ﬂuorinated agents such as
diethylaminosulfur triﬂuoride (DAST) or bis(2-methoxyethyl)-
aminosulfur triﬂuoride (Deoxo-Fluor), a hydroxy−ﬂuorine
interconversion can be eﬀected. Hydroxylated β-amino acids
are excellent, readily available precursors for this purpose. Thus,
on treatment with DAST, 3-hydroxylated cyclohexene β-amino
ester 253 reacted via an SN2′ mechanism to give 5-ﬂuoro-2-
aminocyclohexenecarboxylate 262, while the corresponding
saturated derivative 261 underwent inversion under similar
conditions and yielded 3-ﬂuorinated β-aminocyclohexanecar-
boxylic ester 263 (Scheme 50).65
As discussed earlier (Scheme 10), geminal diﬂuorinated
cyclic β-amino acids have been synthetized eﬃciently from
diﬂuorinated imidoyl chloride synthons by metathesis as key
step. However, the hydroxylated β-aminocyclohexanecarboxylic
esters presented above (Figure 16) could be used not only for
the synthesis of monoﬂuorinated compounds but also for the
direct preparation of diﬂuorinated amino esters via the
corresponding oxo derivatives. For example, oxidation of the
hydroxy group in hydroxylated amino ester 261 gave rise to oxo
ester 264, which on treatment with Deoxo-Fluor underwent
ﬂuorination to furnish diﬂuorinated amino ester 265 (Scheme
51).65
Both of the above approaches for the synthesis of mono- or
diﬂuorinated 2-aminocyclohexanecarboxylates were also ex-
Scheme 47. Synthesis of 5-Hydroxylated 2-
Aminocyclohexanecarboxylic Acid via Iodolactonization
Scheme 48. Synthesis of a 5-Hydroxylated Cyclohexene Amino Ester via Iodolactonization
Figure 16. Structures of hydroxylated 2-aminocyclohexenecarbox-
ylates.
Scheme 49. Synthesis of an Orthogonally Protected 2,5-
Diaminocyclohexanecarboxylic Ester
Figure 17. Structures of orthogonally protected 2,5-diaminocyclohex-
anecarboxylic esters.
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cellent methods for the synthesis of a series of other novel
ﬂuorine-containing six-membered cyclic β-amino acid regio-
and stereoisomers, from either 1,3-cyclohexadiene- or 1,4-
cyclohexadiene-derived bicyclic β-lactam through selective
iodolactonization and hydroxylation followed by hydroxy−
ﬂuorine or oxo−ﬂuorine exchange.65,69
The regio- and stereoselective iodolactonization oﬀered an
opportunity for the selective preparation of epoxycyclohexane
β-amino acids.70 As an example, iodolactone 267 derived from
amino acid 266 under basic conditions took part in lactone
opening, followed by intramolecular iodine displacement with a
hydroxyl group, and easily furnished epoxy amino acid 268
(Scheme 52), which would otherwise have not been possible to
synthetize by the direct epoxidation of 266 with peracids.70
2.4.1.2. Functionalization via Selective Iodooxazinone
and Iodooxazoline Formation. Another method in which
the key step is the functionalization of the C−C ring double
bond of a cyclic β-amino acid derivative with iodine or N-
iodosuccinimide (NIS), followed by intramolecular nucleo-
philic ring closure, is iodooxazination or iodooxazoline
formation. In contrast with iodolactone formation, in this
type of functionalization the starting materials are the N-
protected amino esters, in which the absence of the carboxylate
nucleophile leads to the carbamate O-atom functioning as a
nucleophilic center. Another eﬃcient route for the synthesis of
hydroxylated β-aminocyclohexanecarboxylic acids was based on
iodooxazine formation.
Amino ester 269 reacted with NIS to give oxazinone
derivative 270 regio- and stereoselectively. After dehalogena-
tion with nBu3SnH, followed by simultaneous oxazinone
opening and ester hydrolysis in the presence of aqueous HCl,
this heterocyclic derivative aﬀorded 4-hydroxylated 2-amino-
cylohexancarboxylic acid 272 (Scheme 53).62,71 The particular
beneﬁt of the iodooxazination method in comparison with
iodolactonization (where 5-hydroxylated derivatives were
formed) lay in the possibility of the preparation of a 4-
hydroxylated cyclohexanecarboxylic amino acid.
When the starting derivative contained an amide function
instead of a carbamate group, the above procedure involved not
iodooxazinone nor iodooxazolinone, but oxazine or oxazoline
formation. Thus, on treatment with N-bromosuccinimide
(NBS), amino ester 273 provided bromooxazoline 274,
which was next converted to hydroxylated β-aminocyclopenta-
necarboxylic acid 276 (Scheme 54).72
The iodooxazination and iodooxazolination method was
readily utilized for the synthesis of a series of other
hydroxylated ﬁve- and six-membered carbocyclic amino acid
regio- and stereoisomers and for bicyclic norbornane
derivatives.63
A novel route to hydroxylated cyclohexane β-amino acids,
based on selective oxazoline formation, though not with
electrophile (iodine)-induced cyclization, started from trichlor-
oimidate 277. A base-initiated ring closure by a Michael
addition aﬀorded oxazolines 278 (cis:trans = 73:27). The
oxazoline stereoisomers were separated by chromatography and
submitted to acidic ring-opening to give 3-hydroxylated β-
aminocyclohexanecarboxylic acid derivatives 279−281
(Scheme 55). With the use of this strategy, hydroxylated ﬁve-
membered carbocyclic β-amino acids were also prepared.73
Scheme 50. Syntheses of Fluorinated Cyclohexane 2-
Aminocarboxylates
Scheme 51. Synthesis of a Diﬂuorinated 2-
Aminocyclohexane Amino Ester
Scheme 52. Synthesis of an Epoxy Amino Acid with a
Cyclohexane Skeleton
Scheme 53. Synthesis of a 4-Hydroxylated 2-
Aminocyclohexanecarboxylic Acid via Iodooxazinone
Formation
Scheme 54. Synthesis of a 3-Hydroxylated 2-
Aminocyclopentanecarboxylic Acid
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2.4.1.3. Functionalization via Selective Iodolactamization.
Campbell et al. reported a special functionalization procedure
for cyclohexenecarboxylic acid derivative 282, based on regio-
and stereoselective iodolactamization. On treatment with nBuLi
and I2, N-protected amide 282 furnished iodolactam 283.
Subsequent reductive deiodination and lactam opening resulted
in the orthogonally protected cyclohexane diamino alcohol 285
(Scheme 56).74
2.4.1.4. Functionalization via Stereoselective Epoxidation
and Regioselective Oxirane Opening. Another broadly
applicable and successful method for the synthesis of highly
functionalized carbocyclic β-amino acids starts with stereo-
selective epoxidation of the ring C−C double bond, followed
by regioselective oxirane ring-opening. In 2003, Steel and co-
workers reported the enantioselective synthesis of a hydroxy-
lated carbocyclic β-amino acid derivative, the antibiotic
oryzoxymycin [(−)-238]. Enantioselective hydrolysis (pig-
liver esterase, PLE) and ring-opening under basic conditions
of a β-amino ester with an oxabicyclic framework (286) led to
hydroxylated amino acid enantiomers 287 and 288 in an
approximate ratio of 1:1. Enantiomer 287 was the intermediate
for the preparation of (−)-oryzoxymycin (Scheme 57).75
Other stereoisomers and saturated counterparts of 287 were
prepared analogously.76
The hydroxylated β-amino esters synthetized by the above
procedures were subjected to epoxidation by the same group of
authors. For example, the selective oxidation of 287 with m-
chloroperbenzoic acid (mCPBA) in CH2Cl2 gave epoxyamino
ester diastereoisomers 289:290 in a ratio of 9:1 (77%), whereas
in the more polar solvent MeCN the ratio of the products was
1:2 (95%) (Scheme 58). After separation of the two
diastereoisomers (289 and 290), under catalytic hydrogenation
conditions they participated in simultaneous oleﬁnic bond
saturation and oxirane opening in the presence of Ac2O to
result in diacetoxylated β-amino esters 291 and 29277
Formation of a polyacetoxylated cyclohexane β-amino ester
was reported by the same group of authors: epoxidation of 293
(derived from the di-exo analog of 286 by treatment with BF3·
OEt2 in Ac2O) as the key step proceeded cis-selectively as
concerns the carbamate to give 294 as the major isomer
(294:295 = 9:1). Compound 294 was next submitted to
oxirane opening by hydrolysis under acidic conditions, followed
by acetylation to furnish 296 (Scheme 59).77
An alternative procedure to iodolactonization and iodoox-
azination (see earlier) for the selective introduction of a
hydroxy group onto the skeleton of a cyclic β-amino acid
consists of stereoselective ring C−C double bond epoxidation,
followed by regioselective oxirane opening. Thanks to the H-
bonding directing eﬀect of the carbamate, treatment of trans-
amino ester 297 with mCPBA cis-stereoselectively aﬀorded
Scheme 55. Syntheses of Hydroxylated 2-
Aminocyclohexanecarboxylates via Oxazoline Formation
Scheme 56. Iodolactamization of a β-
Aminocyclohexenecarboxylate
Scheme 57. Syntheses of Hydroxylated β-
Aminocyclohexadienecarboxylic Acids
Scheme 58. Syntheses of Acetoxylated β-
Aminocyclohexanecarboxylates
Scheme 59. Synthesis of a Polyacetoxylated β-
Aminocyclohexanecarboxylic Ester
Chemical Reviews Review
dx.doi.org/10.1021/cr300454h | Chem. Rev. 2014, 114, 1116−11691134
epoxy derivative 298, in which the oxirane ring and the
carbamate at C-2 are in a cis stereochemical arrangement.
Compound 298 reacted with NaBH4 (as a hydride source) to
undergo regioselective oxirane opening, leading to 5-hydroxy-
lated 2-aminocyclohexanecarboxylate 299, the ester hydrolysis
and N-deprotection of which aﬀorded hydroxylated amino acid
300 (Scheme 60).78
The crucial step in the synthesis of other hydroxylated cyclic
β-amino acids was cis-selective epoxidation, followed by
regioselective oxirane opening. Thus, under conditions similar
to those described in Scheme 60, ethyl cis-2-benzyloxycarbo-
nylaminocyclohexenecarboxylate, a stereoisomer of 297, led
selectively to all-cis-4-hydroxylated 2-aminocyclohexanecarbox-
ylic acid and its C-1 epimer.79 These hydroxylated amino acids
were also prepared in enantiomerically pure form. The starting
enantiomerically pure cyclohexene amino acid was obtained by
enzymatic hydrolysis or the corresponding bicyclic lactam
opening reaction, followed by esteriﬁcation and N-protection.
On application of the same processes as for the racemic
compounds, the desired hydroxylated cyclohexane β-amino
acid enantiomers were ﬁnally obtained.78,79
Not only cis-selective but also trans-selective epoxidation can
be eﬃciently utilized for the stereo- and regioselective
hydroxylation of carbocyclic amino acids. Epoxidation of the
oleﬁnic bond of N-protected bicyclic lactam 301 was achieved
stereoselectively with opposite selectivity, with the formation of
trans-epoxy derivative 302, in which the oxirane and carbamate
are in a trans steric arrangement. Lactam ring-opening with
NaOEt under diﬀerent conditions provided epoxy amino ester
303 and its C-1 epimer 304, the oxirane opening of which
under reductive conditions with NaBH4 permitted the
preparation of other novel hydroxylated cyclohexane β-amino
acid derivatives (305 and 306) (Scheme 61).79
Selective epoxidation proved to be an eﬃcient method not
only for hydroxylation but also for the introduction of other
functional groups onto the carbocycle of a β-amino acid. Three
useful epoxy β-amino ester stereoisomer intermediates (307−
309) for this purpose were prepared from 2-aminocyclopente-
necarboxylic acid or from a cyclopentadiene-derived bicyclic β-
lactam by means of epoxidation based on opposite selectivities
(Figure 18).80
These epoxy amino esters were then subjected to azidolysis
with NaN3, resulting regioselectively in the corresponding 4-
azido-substituted β-amino esters 310−313 (Figure 19).80
These compounds can be regarded as orthogonally protected
β,γ-diaminocarboxylic acid derivatives.
The enantiomers of the above azido esters were also
prepared by starting from the corresponding enantiopure
cyclopentene β-amino acid, which was prepared by enzymatic
resolution of its bicyclic β-lactam precursor.80
An optically active 1,2,3-triazole-substituted cispentacin
derivative was synthetized when azido amino ester enantiomer
310 was reacted with symmetrical diethyl acetylenedicarbox-
ylate through an azide−alkyne 1,3-dipolar cycloaddition. The
reaction took place readily in reﬂuxing EtOH to give
enantiopure 314 (Scheme 62). Analogously, azido esters
stereoisomers 311−313 were converted to the corresponding
triazole-functionalized cyclopentane β-amino acid derivatives.81
Other 1,2,3-triazole-substituted cispentacins were synthetized
when the earlier prepared azido cyclopentane amino esters
were reacted with unsymmetrical acetylenes. Thus, the reaction
of azido ester 310 with ethyl propiolate (R1 = CO2Et, R
2 = H)
under thermal conditions without the addition of a Cu(I)
Scheme 60. Synthesis of a Hydroxylated β-Amino Acid via
Selective Epoxidation and Oxirane Opening
Scheme 61. Syntheses of Hydroxylated β-Amino Acids via
Selective Epoxidation and Oxirane Opening
Figure 18. Structures of epoxy β-aminocyclopentanecarboxylates.
Figure 19. Structures of Azido β-Aminocyclopentanecarboxylates.
Scheme 62. Syntheses of 1,2,3-Triazole-Substituted
Cispentacins via Azide−Alkyne Dipolar Cycloaddition
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catalyst furnished 1,4-disubstituted 1,2,3-triazole derivative 315
regioselectively. With other acetylenes, however, when R1 = Pr
or Ph and R2 = H, the reaction proceeded with CuI to give 1,4-
disubstituted triazole derivatives 316 and 317 regioselectively
(Scheme 62).82
Azidolysis of epoxycyclohexane β-amino ester 318 in the
presence of NH4Cl proceeded smoothly to aﬀord 5-azido ester
319 100% regioselectively (Scheme 63). However, when AlCl3
was used as additive in this reaction, the coordinating ability of
Al and the diaxial preferred conformations during the oxirane
opening of the epoxycyclohexane meant that the reaction gave
rise to a mixture of azido ester regioisomers 319 and 320 in a
ratio of 1:1; these were separated and isolated by chromatog-
raphy (Scheme 63).83
A nitrile function can be introduced on the carbocycle of a β-
amino acid by starting from epoxy amino esters. Thus,
treatment with Et2AlCN epoxide 318 furnished two
regioisomers, the 4- and 5-nitrile-substituted products, in a
ratio of approximately 2.5:1.83 However, when epoxide 321
underwent oxirane opening under similar conditions, 322 was
formed 100% regioselectively (Scheme 64).83
A series of other novel nitrile- and azide-functionalized
cyclohexane amino ester regio- and stereoisomers have been
synthetized in racemic and enantiomerically pure form.83
2.4.1.5. Functionalization via Stereoselective Dihydrox-
ylation. Hydrolysis of optically active cis-amino acid derivative
323, benzyl esteriﬁcation, and cis-dihydroxylation in the
presence of OsO4 resulted in dihydroxylated β-amino ester
324, in which the two hydroxy groups are oriented trans to the
ester and carbamate functions. Transformation of Diels−Alder
cycloadduct 325 by formyl group oxidation, benzyl ester
formation, and dihydroxylation furnished the same amino ester
324 (Scheme 65).84
Dihydroxylated alicyclic β-amino esters in which the relative
steric arrangement of the two hydroxyl groups is trans were
prepared by the same group of authors by hydroxylactonization
and lactone opening. Thus, ester hydrolysis of 326, followed by
epoxidation and oxirane opening, yielded hydroxylactone 327
stereo- and regioselectively. Lactone opening with MeOH in
the presence of NaHCO3 provided dihydroxylated β-amino
ester 328, in which the hydroxy groups are in a trans steric
arrangement (Scheme 66).84
Dihydroxylation of cis-2-aminocyclopentenecarboxylic ester
329 with NMO/OsO4 proceeded stereoselectively with the
formation of dihydroxy amino ester 330, in which the two
hydroxy groups are in a trans relationship with the ester and
carbamate. Simultanous N-deprotection and ester hydrolysis
under acidic conditions led to dihydroxylated cispentacin 331.
In contrast, dihydroxylation of trans-amino ester 332, which
was obtained by epimerization of 329 at C-1 with NaOEt,
resulted stereoselectively in dihydroxylated amino ester 333, in
which both hydroxy functions are oriented cis to the carbamate.
Ester hydrolysis and Boc deprotection in acidic medium gave
dihydroxylated transpentacin 334, a stereoisomer of 331
(Scheme 67).72
The above dihydroxylated cyclopentane β-amino acids were
also prepared in enantiomerically pure form. Starting from the
racemic bicyclic β-lactam, enzymatic lactam opening and then
esteriﬁcation and N-Boc protection led to optically pure amino
ester 329. Following the synthetic steps presented in Scheme
67, enantiomerically pure dihydroxylated amino acids were
accessed.72
Analogously to the methodology presented above, various
dihydroxylated cyclohexane β-amino acid regio- and stereo-
isomers were also synthetized by OsO4-catalyzed dihydrox-
ylation.85 The vicinal dihydroxylated carbocyclic β-amino-
Scheme 63. Syntheses of Azido β-
Aminocyclohexanecarboxylic Esters
Scheme 64. Synthesis of a Nitrile-Substituted β-Amino Ester
Scheme 65. Synthesis of a Cis-Dihydroxylated β-Aminocyclohexanecarboxylate
Scheme 66. Synthesis of a trans-Dihydroxylated β-
Aminocyclohexanecarboxylate
Scheme 67. Syntheses of Dihydroxylated β-
Aminocyclopentanecarboxylic Acids
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carboxylic esters proved to be valuable synthons for the
preparation of N-heterocyclic β-amino acid derivatives (see
sections 3.1.3.5 and 3.1.4).
2.4.1.6. Functionalization via 1,3-Dipolar Cycloaddition.
1,3-Dipolar cycloaddition of nitrile oxides to a C−C double
bond is a widely used eﬃcient method for the construction of
an isoxazoline skeleton and has also been utilized for
functionalization of the oleﬁnic bond of carbocyclic β-amino
acids. Isoxazoline-fused cispentacins were synthetized by this
methodology. Addition of nitrile oxide generated from
nitroethane with Boc2O/DMAP to ethyl cis-2-aminocyclohex-
enecarboxylate (329) yielded three of the four possible regio-
and stereoisomers, 335, 336 and 337, in a ratio of 6:1:0.7
(Scheme 68). These compounds were separated and isolated
by means of chromatography.86
However, when the reaction was carried out under similar
conditions with ethyl trans-2-aminocyclopentenecarboxylate,
the C-1 epimer of 329, the cycloaddition was 100% selective,
furnishing only one cycloaddition product, which could also be
prepared by epimerization of the minor derivative 337.87
Moreover, cycloaddition to 329 with the nitrile oxide generated
from PhNCO and Et3N resulted 100% regio- and stereo-
selectively in isoxazoline-fused derivative 335.87
The synthetic procedure designated to obtain isoxazoline-
fused cispentacin derivatives was extended to the preparation of
the enantiomerically pure substances. Enzymatic lactam
opening of the racemic bicyclic β-lactam, followed by
esteriﬁcation and N-protection, aﬀorded optically pure amino
ester 329, which was next submitted to dipolar cycloaddition,
leading to optically pure isoxazoline-fused cispentacins.87
The enormous advantage of the dipolar cycloaddition of
nitrile oxide to cycloalkene β-amino acids lies in the
opportunity for the selective preparation of highly function-
alized derivatives of this class of compounds by isoxazoline ring
transformation. When subjected to heterocycle opening under
reductive conditions with concomitant imine hydrolysis in the
presence of HCO2NH4 and Pd/C as catalyst, isoxazoline-fused
cispentacin derivative 335 aﬀorded oxo amino ester 338
(Scheme 69).88
On modiﬁcation of the reductive conditions to NaBH4/
NiCl2, 335 underwent stereoselective isoxazoline opening with
the generation of a new stereogenic center to give the highly
functionalized cispentacin 339 in good yield (Scheme 70).88
The syntheses of several highly functionalized cispentacin
stereoisomers (340−343) were also carried out from other
isoxazoline-fused amino ester regio- and stereosiomers (Figure
20).88
2.4.2. Several Relevant Routes to Functionalized
Cyclic β-Amino Acids Other Than Functionalization of
the Ring C−C Double Bond. Functionalized carbocyclic β-
amino acids have not only been obtained by transformation of
the ring C−C double bond. The most relevant other routes
were mentioned earlier in connection with the most general
approaches to this class of compounds.2a,7,14,15,20 Polyhydroxy-
lated alicyclic β-amino acid stereoisomers were prepared in
enantiomerically pure form from optically pure nitrohexofura-
noses in eight or nine steps.89 Azidolysis of α,β-epoxycyclohex-
anecarboxylic acids in a metal-catalyzed one-pot reaction
aﬀorded cyclohexane α-hydroxy-β-amino acids.90 Another
route to substituted alicyclic β-amino acids is based on a
stereocontrolled three-component reaction. The CAN-cata-
lyzed one-pot reactions between alkylamines, β-keto esters, and
chalcones gave cis-4,5-disubstituted 2-aminocyclohexanecarbox-
ylates.91
3. CYCLIC β-AMINO ACIDS WITH A HETEROATOM IN
THE RING
Although slightly less abundant than their carbocyclic analogs,
the heterocyclic β-amino acids are an interesting class of
derivatives because of their important biological activities, and
an ever-increasing number of publications have appeared on
these compounds during the past 10 years. As an example, the
four-membered cyclic β-amino acid with an O atom in the ring,
(2R,3S)-3-aminooxetane-2-carboxylic acid or oxetin (344),
exhibits antibiotic and herbicidal activity (Figure 21).92
The unsubstituted β-amino acid with a pyrrolidine frame-
work (APC, 345; Figure 21) has been used in combination
with ACPC (β-aminocyclopentanecarboxylic acid) as a building
element in the construction of novel peptides with antimicro-
bial activities.93 A number of the functionalized pyrrolidine-
based β-amino acids (e.g., 346) are known to be eﬃcient
TACE inhibitors and also display antitumoral activity (see ref
94 and references cited therein).
Scheme 68. Syntheses of Isoxazoline-Fused Cispentacin Derivatives
Scheme 69. Reduction of an Isoxazoline-Fused Cispentacin
Derivative
Scheme 70. Formation of a Highly Functionalized
Cispentacin Derivative from an Isoxazoline-Fused Precursor
Figure 20. Structures of highly functionalized cispentacin derivatives.
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Other heterocyclic β-amino acids (Figure 22; see also section
3.2.3.2) are key elements in many bioactive products. Some of
them are nucleoside-based antibiotics, e.g., blasticidin S (347),
gougerotin (348), and chryscandin (349) (see ref 95 and
references cited therein). The pyran-based β-amino acids have
been gaining in importance as analogs of the antiviral agent
zanamivir (350; Figure 22; see also section 3.2.3.3).96
3.1. Syntheses of Cyclic β-Amino Acids with a N Atom in
the Ring
Among the large number of synthetic methods available for the
preparation of heterocyclic β-amino acids in which the
carboxylic and the amino functions are connected to stereo-
genic C-centers, several are analogous to procedures already
described for their carbocyclic counterparts, but many trans-
formations are speciﬁc methods that depend on the heteroatom
(N or O) and the ring size.
3.1.1. Three- and Four-Membered N-Containing
Cyclic β-Amino Acids. Analogously to the cyclopropane β-
amino acids, the heterocyclic substances containing an N atom
are unstable derivatives, which in general tend to serve as
intermediates for the preparation of other derivatives. Thus,
addition of ethyl N-((4-nitrobenzenesulfonyl)oxy)carbamate
(NsONHCO2Et) to unsaturated amino ester 351 leads to an
aziridine intermediate 352, which readily undergoes hydrolysis
to give oxo amino ester 353 (Scheme 71).97
Azirine carboxylate 354 has been used as an alkylating agent
for diﬀerent amines. When 354 was treated with amines in the
presence of Na2CO3, the products were aziridine amino
carboxylates 355, which could be easily transformed to various
other derivatives (Scheme 72).98
β-Amino acids containing the four-membered azetidinone
skeleton are elements of peptide-based antitumoral antibiotics,
e.g., deoxybouvardin (a bicyclic hexapeptide) analogs. Azetidi-
none amino ester enantiomer 362 was prepared from chiral
oxazolidinone 356, which was converted in a Staudinger
reaction to β-lactam derivative 358. Ozonolyis and formyl
group reduction gave 359, which was subjected to reductive
conditions, N-protection, hydroxymethyl oxidation, and ester-
iﬁcation to furnish 362 (Scheme 73).99
Et2AlCl-promoted coupling of imine 363, followed by ring
closure of the syn and anti adduct mixture of 364 in the
presence of i-PrMgBr, resulted in a mixture of trans- and cis-
azetidinone β-amino carboxylates, 365 and 366 (Scheme
74).100
Four-membered N-heterocyclic β-amino acid derivatives
have been synthetized from α-amino-β,γ-aziridino esters by
an aziridine ring-opening ring-closure protocol. When heated in
MeCN in the presence of Et3N, aziridine derivatives 367,
obtained by the addition of glycine esters to α-chlorotosyli-
mines followed by imine reduction,101 furnished azetidine β-
amino esters 368 (Scheme 75).5a
The asymmetric version of this method starts from the
optically active α-chlorinated toluenesulfynimine, which reacts
with glycine esters via aziridine derivative 369 to give azetidine
β-amino acid enantiomer 370 (Scheme 75).5b
3.1.2. Five-Membered N-Containing Cyclic β-Amino
Acids. In contrast with the three- and four-membered
heterocyclic β-amino acids, the ﬁve-membered N-heterocyclic
β-amino acids comprise a large group of compounds.
Accordingly, the range of synthetic methods applied to access
this class of products is far wider. The following sections will
describe the most generally applicable synthetic routes,
together with several special methodologies.
3.1.2.1. Synthesis by Amino Group Conjugate Addition.
The procedure discussed in section 2.1.3 for amino group
conjugate addition to unsaturated carbocyclic esters is also an
eﬃcient general method for the construction of ﬁve-membered
N-heterocyclic β-amino acids. N-Heterocyclic unsaturated ester
371, prepared by reductive deoxygenation of the corresponding
oxo ester, was a suitable starting compound for this purpose.
Michael addition of (R)-α-methylbenzylamine to α,β-unsatu-
Figure 21. Some bioactive heterocyclic β-amino acids.
Figure 22. Several bioactive compounds with a β-amino acid element
in their structure.
Scheme 71. Transformation of an Aziridine β-Amino Acid
Intermediate
Scheme 72. Three-Membered N-Heterocyclic β-Amino
Acids
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rated ester 371 aﬀorded a trans-amino ester derivative
containing a pyrrolidine ring, 372. After removal of the chiral
auxiliary by reductive methods, amino ester enantiomer 373
was obtained (Scheme 76).102
β-Aminopyrrolidinecarboxylic acid (APC) and β-amino-
cyclopentanecarboxylic acid (ACPC) have been used as
building residues for the construction of β-peptide
oligomers.93,103
A rather interesting process with regard to the products of
conjugate addition was observed when lithium dibenzylamide
was added to unsaturated tert-butyl ester 377. Ester 377 was
obtained by the Michael addition−condensation of glycine
ester 374 and reaction with tert-butyl acrylate, via the
corresponding enolate 375. In contrast with the addition of
(R)-α-methylbenzylamine (see Scheme 76), treatment of 377
with lithium dibenzylamide at −78 °C yielded the cis-amino
ester derivative 378 as the major product, along with pyrroline
(379) and pyrrole (380) compounds as minor derivatives
(Scheme 77).104 Such cis-selective addition was also observed
when lithium (S)-N-benzyl-N-α-methylbenzylamide was added
to ester 381, with the formation of β-amino acid derivative 382.
The trans counterpart 383 could be readily prepared by the
isomerization of 382 at C-1 in the presence of t-BuOK in
reﬂuxing t-BuOH. Reductive removal of the chiral auxiliary and
ester deprotection in both 382 and 383 led to the pyrrolidine
β-amino acid enantiomers cis-384 and trans-385 (Scheme
78).104
Scheme 73. Synthesis of a β-Amino Acid Containing an Azetidinone Ring
Scheme 74. Syntheses of β-Amino Acid Derivatives Containing an Azetidinone Skeleton
Scheme 75. Syntheses of β-Amino Acid Derivatives
Containing an Azetidine Skeleton
Scheme 76. Synthesis of Pyrrolidine β-Amino Esters by
Conjugate Addition to an Unsaturated Ester
Scheme 77. Synthesis of an Orthogonally Protected
Pyrrolidine β-Amino Ester via Lithium Amide Addition to an
Unsaturated Ester
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These heterocyclic β-amino acids are themselves bioactive
derivatives; for example, cis-4-aminopyrrolidine-3-carboxylic
acid (384) is a GABA (γ-aminobutyric acid) receptor, while
cis-N-Boc-4-aminopyrrolidine-3-carboxylic acid (386) is a
modest inﬂuenza neuraminidase inhibitor. They additionally
serve as precursors for the synthesis of other important active
inﬂuenza neuraminidase inhibitors, such as 387 (Figure 23).104
Amine conjugate addition to α,β-unsaturated esters was also
eﬃciently applied for the synthesis of pyrrolidine β-amino
acids. Unsaturated amino ester 388 underwent Michael
addition on reaction with chiral amine 389, leading to products
390 and 391 in a ratio of 1:1, which were separated by
chromatography. Cleavage of the trichloroacetyl group under
basic conditions, esteriﬁcation with diazomethane, and
oxidative removal of the chiral auxiliary resulted in β-amino
ester enantiomer 392, containing a γ-lactam skeleton (Scheme
79).105
The same research group utilized analogous methods to
prepare other pyrrolidinone-based β-amino acid stereoisomers
as conformationally restricted analogs of aspartic acid and
peptidomimetics for the synthesis of novel β-foldamers.106
Enantiomerically pure 1-oxyl-2,2,5,5-tetramethylpyrrolidine-
carboxylic acids were also synthetized as spin-labeled β-amino
acids (399 and 400) by a conjugate addition procedure. α,β-
Unsaturated nitrile 394 derived from amide 393 underwent
NH3 addition to give racemic amino nitrile 395, in which the
amino and nitrile functions are in a trans relationship. Nitrile
hydrolysis and amine protection with Fmoc furnished amino
acid 396. This was next reacted with the chiral (R)-2,2′-
dihydroxy-1,1′-binaphthyl in the presence of 1-(3-dimethyla-
minopropyl)-3-ethylcarbodiimide (EDC) and DMAP to aﬀord
amino ester diastereomers 397 and 398, which were separated
and isolated by means of chromatography. Next, removal of the
chiral auxiliary by basic hydrolysis, N-Fmoc protection, and
esteriﬁcation with 7-aza-1-hydroxy-1,2,3-benzotriazole (HOAt),
N-methylmorpholine (NMM), and EDC resulted in amino
ester enantiomers 399 and 400 (Scheme 80).107
3.1.2.2. Syntheses by Cycloaddition. Intramolecular 1,3-
dipolar nitrone cycloaddition to an chiral ketene dithioacetal
Scheme 78. Syntheses of cis- and trans-Pyrrolidine β-Amino Acid Enantiomers by Chiral Lithium Amide Conjugate Addition
Figure 23. Structures of some bioactive pyrrolidine β-amino acids.
Scheme 79. Synthesis of a Pyrrolidinone trans-β-Amino Acid
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dioxide was the crucial step for the preparation of pyrrolidine β-
amino acids. Amino acetal 403, containing a formyl moiety,
derived from 401 by allylation and oxidative C−C bond
cleavage, was reacted with chiral phosphonate 404 to give 405.
Treatment of 405 with p-TsOH and N-benzylhydroxylamine
(BnNHOH) led through the corresponding nitrone inter-
mediate by intramolecular 1,3-dipolar cycloaddition to
isoxazolidine-fused pyrrolidine derivative 406. Under reductive
conditions, with isoxazolidine opening, followed by removal of
the N-protecting groups, 406 furnished the N-heterocyclic
amino acid enantiomer 408 (Scheme 81).30a
The construction of an isoxazolidine-fused pyrrolidine ring
via intramolecular nitrone 1,3-dipolar cycloaddition was the key
step in the synthesis of orthogonally protected amino acid
enantiomer 413. Unsaturated aldehyde 409 was reacted with
chiral hydroxylamine derivative 410 via nitrone formation to
obtain isoxazolidine diastereoisomers 411 and 412 regioselec-
tively in a ratio of 96:4. After separation from the minor
derivative, hydrogenolysis of 411, N-protection, and oxidation
provided pyrrolidine β-amino acid enantiomer 413 (Scheme
82).108
The pyrrolidine skeleton of N-heterocyclic β-amino acids can
be eﬃciently created by azo-methinylide (3 + 2)-cycloaddition
of benzylglycine to benzyl methyl maleate (414). N-
Benzylglycine and paraformaldehyde were reacted with ester
414 to obtain 415, the debenzylation and N-Boc protection of
which resulted in its half-ester. Curtius rearrangement of this
gave pyrrolidine β-amino ester 416, which was next coupled
with carboxylic acid derivative 417 to furnish ester 418. N-Boc
deprotection of 418 and its conversion to hydroxymic acid
aﬀorded 419, a selective inhibitor of the TNF-α converting
enzyme (Scheme 83).2k A series of similar bioactive products
Scheme 80. Syntheses of 1-Oxylpyrrolidine β-Amino Acids
Scheme 81. Synthesis of a cis-β-Amino Acid Containing a
Pyrrolidine Core from Ketene Dithioacetal Dioxide
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containing a pyrrolidine β-amino acid element have also been
synthetized and investigated.109
3.1.2.3. Syntheses from β-Keto Esters. Alicylic β-oxo esters
are convenient starting compounds for preparation of the
corresponding ﬁve- or six-membered β-amino acids (see section
2.1.1). Cyclic β-oxo esters with an N atom in the ring are also
suitable precursors for the preparation of N-heterocyclic β-
amino acids. This is one of the most common routes to this
class of compounds. Amination of enolate 420 (prepared as
presented in Scheme 77) with benzylamine and AcOH in
MeOH furnished enamino ester 421, the cis-selective reduction
of which with NaBH4 provided pyrrolidine β-amino ester 422,
in which the ester and amino functions are in a cis relationship.
This compound could be readily converted to an orthogonally
protected amino acid 424 (Scheme 84).110a
Various pyrrolidine β-amino acid analogs that behave as
neuramidase inhibitors have been synthetized by the β-keto
ester reduction methodology.60b,110
The asymmetric variation of the β-keto ester transformation
procedure for the preparation of β-amino acids containing a
pyrrolidine ring was eﬃciently applied by Gellman and co-
workers for the synthesis of these compounds in optically pure
form. N-Cyclic oxo ester 425 was reacted with (R)-(+)-α-
methylbenzylamine to give enamine 426, the reduction of
which proceeded trans-selectively and led to trans-β-amino
ester derivative 427. Ester hydrolysis of 427, chiral auxiliary
removal, and N-Fmoc protection furnished the optically pure,
orthogonally protected pyrrolidine β-amino ester 429 (Scheme
85).111
Scheme 82. Synthesis of an Orthogonally Protected
Pyrrolidine β-Amino Acid by Intramolecular Cycloaddition
in a Nitrone Precursor
Scheme 83. Synthesis of a Bioactive Compound Containing a Pyrrolidine β-Amino Acid Element
Scheme 84. Synthesis of a cis-β-Amino Acid Containing a
Pyrrolidine Skeleton from an Oxo Ester
Scheme 85. Synthesis of a trans-β-Amino Acid Enantiomer
Containing a Pyrrolidine Skeleton from an Oxo Ester
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Similar transformations were performed by starting from
420, with (S)-(−)-α-methylbenzylamine as chiral auxiliary.6
The chiral N-heterocyclic β-amino acid was applied for the
synthesis of peptide oligomers in combination with its
carbocyclic analog or with nucleoside β-amino acid analogs.112
Pyrrolidine β-amino acids with an attached carbohydrate
were incorporated into peptide sequences with 2-amino-
cyclopentanecarboxylic acid (ACPC), forming a 12-helical
foldamer in aqueous solution. Amino ester 427, synthetized
from the corresponding oxo ester, was converted to 430 by
ethyl ester hydrolysis, benzyl ester formation, Boc-deprotection,
and N-sulfonamide formation. The sugar moiety was attached
to 430 in a cross-metathesis reaction with unsaturated
monosaccharide 431 (Scheme 86).113
N-Aryl β-enamino esters based on a pyrrolidine skeleton,
synthetized by reductive amination of the corresponding β-oxo
esters, were described as intermediates for the preparation of
diﬀerent carboxylic esters containing the pyrrolo[3,2-b]-
quinoline ring system.114
Besides the use of a chiral auxiliary (Schemes 85 and 86), the
asymmetric syntheses of pyrrolidine β-amino acids can also be
achieved by enantioselective reduction of β-enamino esters 433
with a Ru catalyst in the presence of a chiral phosphine ligand
(see Scheme 4 for carbocyclic analogs). The reduction of
enamine 433 resulted in optically pure 434 with an ee value of
95% (Scheme 87).8
3.1.2.4. Syntheses by Intramolecular Radical Cyclization.
Sulfanyl radical addition−cyclization of oxime ethers linked to
alkenes through an N atom (435) yielded cis- and trans-
cyclized products 436 and 437 in a ratio of 3:1. After separation
of these diastereoisomers, trans isomer 437 was subjected to N-
Boc protection and oxidation with mCPBA to give sulfoxide
derivative 439. Acidic hydrolysis of 439 next aﬀorded aldehyde
440, whose formyl moiety was oxidized to give the
corresponding ester 441. Cleavage of the oxime ether, followed
by ester hydrolysis and N-Boc deprotection, led to β-amino
acid 442 (Scheme 88).42
The above intramolecular radical cyclization protocol has
likewise been used to synthetize other novel substituted
pyrrolidine β-amino acids.42
3.1.2.5. Syntheses from Hydroxylated Proline Precursors.
Optically active hydroxylated prolines are eﬃcient and
important precursors for the preparation of pyrrolidine β-
amino acids in enantiomerically pure form. After N-Cbz
protection, benzyl ester formation, and elimination via the
tosylate, trans-4-hydroxy-L-proline (443) furnished the unsatu-
rated proline derivative 444. This was next subjected to C−C
double bond functionalization through epoxidation with
mCPBA, to give cis- and trans-epoxy derivatives 445 and 446
in an approximate ratio of 1:2, which were separated by
chromatography. When reacted with NaN3, epoxy amino ester
445 underwent oxirane ring-opening to furnish azido esters 447
and 448 in a ratio of 1:2, the two regioisomers likewise being
separated and isolated by chromatography. Reductive azido
group transformation of 447 readily yielded trans-β-amino acid
enantiomer 449 (Scheme 89).115 It is noteworthy that
azidolysis of 446 led exclusively to a 4-azido derivative, which
did not aﬀord a pyrrolidine β-amino acid.
However, the readily available trans-3-hydroxy-L-proline
oﬀered a possibility for the preparation of other stereoisomers
of pyrrolidine β-amino acid derivatives. When treated with
diphenylphosphoryl azide (DPPA), PPh3, and diethyl azodi-
carboxylate (DEAD), ester 452 derived from hydroxyproline
451 under Mitsunobu reaction conditions underwent inversion
to aﬀord the cis-3-azidoproline methyl ester 453, which can be
regarded as an orthogonally protected β-amino acid derivative
(Scheme 90).116
The synthesis of trans-3-azido proline methyl ester 456, a
stereoisomer of 453, was accomplished from N-Boc-protected
trans-3-hydroxy-L-proline 452 by double inversion. Ester
formation (454) with inversion under Mitsunobu conditions
with 4-nitrobenzoic acid, followed by ester cleavage with NaN3,
led to cis-3-hydroxyproline methyl ester 455, which underwent
hydroxy−azide exchange with inversion in a Mitsunobu
reaction to give azido ester 456 (Scheme 91).116
An alternative route to a cis-hydroxyproline derivative, a
precursor of trans-aminoprolines, was described by Gellman
and co-workers from keto ester 457. The baker’s yeast-
catalyzed reduction of 457 cis-selectively furnished hydroxy
ester 458, which was readily transformed by hydroxy−azide
exchange, followed by reduction of the azido group, to the
corresponding optically pure trans-β-aminoproline derivative
459 (Scheme 92).117
The 3-aminoproline derivatives are important precursors for
the synthesis of other bioactive compounds, such as the
arginine-containing dipeptide amide 464. Amidation of
hydroxyproline 460 by carboxylic group activation with isobutyl
chloroformate (IBCF) and N-methylmorpholine (NMM),
followed by ammonolysis, furnished 461. A double inversion
Mitsunobu reaction and azidolysis, followed by reduction, led
to β-amino acid derivative 463, the coupling of which with Boc-
protected nitroarginine yielded dipeptide 464 (Scheme 93).118
Scheme 86. Synthesis of a Pyrrolidine β-Amino Acid with a
Carbohydrate Moiety
Scheme 87. Synthesis of an Orthogonally Protected
Pyrrolidine β-Amino Acid from the Corresponding Enamine
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3.1.2.6. Syntheses from Carbohydrate Derivative Precur-
sors. Enantiomerically pure functionalized β-aminoproline
derivatives have been synthetized from bicyclic hydroxylated
pyrrolidine-fused β-lactam 465, derived from ascorbic acid in
10 steps. The hydroxy group of 465 was converted to a
benzoyl-protected amino function to give lactam derivative 466.
Azetidinone ring-opening followed by esteriﬁcation with
CH2N2 resulted in orthogonally protected methyl β,γ-
diaminopyrrolidinecarboxylate 467 (Scheme 94).119
An alternative route to 3-aminoproline derivatives from
ascorbic acid was described by Pfeifer et al. (see also section
3.1.2.5). Bicyclic β-lactam 465 was subjected to hydroxy group
removal by transformation to the corresponding triﬂate,
followed by reduction with NaBH4, to give 468. Oxidative
removal of the 2,4-dimethoxybenzyl (DMB) group and
subsequent N-Boc protection furnished azetidinone 469.
Base-catalyzed lactam opening, removal of the Z group by
Scheme 88. Synthesis of a trans-Pyrrolidine β-Amino Acid by Radical Cyclization of an Allylamine Derivative
Scheme 89. Syntheses of Hydroxylated Pyrrolidine β-Amino
Acid Isomers
Scheme 90. Synthesis of an Orthogonally Protected
Pyrrolidine cis-β-Amino Ester from a Hydroxylated Proline
Scheme 91. Synthesis of an Orthogonally Protected
Pyrrolidine trans-β-Amino Ester from a Hydroxylated
Proline Derivative
Scheme 92. Synthesis of an Orthogonally Protected
Pyrrolidine β-Amino Acid from a Hydroxylated Proline
Derivative
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hydrogenolysis, and N-Fmoc protection aﬀorded heterocyclic
β-amino acid derivative 470 (Scheme 95).120
β-Lactam 465 was a suitable precursor for the preparation of
4-hydroxylated 3-aminoproline derivatives, which were then
transformed to various highly substituted pyrrolidine derivatives
with pharmacological potential (Figure 24).121
3.1.2.7. Syntheses by Curtius Rearrangement of Hetero-
cyclic Dicarboxylates. The ﬁve-membered N-heterocyclic
dicarboxylates are excellent precursors for the synthesis of the
corresponding β-amino acid derivatives. The key step in these
transformations is the Curtius rearrangement of one carboxylic
function to the requisite NHZ moiety. One approach to
pyrrolidine dicarboxylates was based on dipolar cycloaddition
of the azomethine ylide of benzylglycine to benzyl methyl
maleate, followed by the sequences presented in Scheme 83,
which resulted in the ﬁve N-heterocyclic β-amino acid
derivatives. Another route to pyrrolidine dicarboxylic esters
(476) started from azetidinone carboxylic acid 475. Removal of
the benzhydryl group of 476, followed by Curtius rearrange-
ment of acyl azide 478, furnished 3-aminoproline derivative
479 (Scheme 96).122
Another pyrrolidine β-amino acid regioisomer was prepared
from half-ester 480 via the Curtius reaction to give 481.
Compound 481 served as a precursor of functionalized
aminopyrrolidine 482, a known factor Xa inhibitor (Scheme
97).123
3.1.3. Six-Membered N-Containing Cyclic β-Amino
Acids. The main synthetic methods available for the
preparation of six-membered N-heterocyclic β-amino acids
exhibit similarities with those presented for the carbocyclic or
ﬁve-membered N-containing cyclic derivatives.
Scheme 93. Synthesis of a Dipeptide Containing a Pyrrolidine β-Amino Acid Element
Scheme 94. Synthesis of a Pyrrolidine β,γ-Diamino Ester from Ascorbic Acid
Scheme 95. Synthesis of an Orthogonally Protected
Pyrrolidine β-Amino Acid Derived from Ascorbic Acid
Figure 24. Several bioactive, highly substituted pyrrolidine derivatives synthetized from 4-hydroxylated 3-aminoproline derivatives.
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3.1.3.1. Syntheses from β-Keto Esters. β-Ketopiperidine
carboxylates are suitable starting materials for the synthesis by
reductive amination of six-membered N-cyclic β-amino acids in
racemic or enantiomerically pure form (see sections 2.1.1 and
3.1.2.3 for alicyclic and N-heterocyclic ﬁve-membered analogs).
Thus, treatment of β-oxopiperidine ester 483 with AcONH4 led
to ester 484, which was a precursor of the selective nonpeptide
ORL-1 antagonist 485 (Scheme 98).124
As presented earlier for the carbocyclic and the ﬁve-
membered N-cyclic analogs, the reductive amination method-
ology can also be extended to the synthesis of the enantiomers,
by using optically active amines as chiral auxiliaries. Reaction of
ester 486 with (R)-1-phenylethylamine provided enamino
carboxylic ester 487. Its reduction under diﬀerent experimental
conditions aﬀorded stereoisomers 488 and 489, the best
selectivity being achieved with NaBH4/TFA at −45 °C
(488:489 = 28:1). The cis isomer 488 could be separated
from the minor trans one 489 by means of chromatography
(Scheme 99).125
Another asymmetric version of the above reaction with
inverse stereoselectivity was reported by Gellman and co-
workers. Upon treatment with (R)-1-phenylethylamine, ethyl
ester 490 gave enamine 491. Reduction of 491 with NaBH4
resulted in a mixture of trans- and cis-piperidine β-amino esters
in a trans:cis ratio of 4:1. Isomerization of the cis derivative
from the mixture aﬀorded trans-β-amino ester 492, and removal
of the chiral auxiliary by transfer hydrogenolysis, ester
hydrolysis, and N-Fmoc protection resulted in amino acid
493, which can be used as a chiral building block in the
synthesis of peptide oligomers (Scheme 100).126
Reduction of the chiral enamine derived from 4-oxopiper-
idine-3-carboxylic acid methyl ester (494) was performed 100%
cis-selectively with the use of NaBH(OAc)3, to yield 488
(Scheme 101).127
Similar experiments involving cis-selective enamine reduction
were executed by starting from the regioisomer methyl 3-
oxopiperidine-4-carboxylate (496). Reductive removal of the
chiral auxiliary in 488 and 497 furnished piperidine β-amino
ester regioisomers 495 and 498 (Schemes 101 and 102).127
Highly cis-selective reduction of piperidine enamino esters
was attained with NaBH(OAc)3 by using the CoCl2 and (S)-
(−)-2,2′-p-tolylphosphino)-1,1′-binaphthyl ((S)-TolBINAP)
catalyst system.127,128
Spin-labeled chiral β-amino acids in the form of nitroxide free
radicals have important applications in medicinal chemistry as
spin labels, oxidizing agents, antioxidants, etc. The six-
membered azaheterocyclic β-amino acids have also been
synthetized by reductive amination of β-keto esters (for the
ﬁve-membered analogs, see Scheme 80) and investigated as
components in the synthesis of β-hexapeptides. Oxo ester 500
(prepared from ketone 499 by treatment with CO2 under basic
conditions, followed by esteriﬁcation) reacted with (R)-α-
methylbenzylamine to yield 501. Reduction of 501 with
NaCNBH3 resulted in a mixture of two cis-β-amino ester
diastereoisomers, which were separated by crystallization to
provide pure 502 and 503 (Scheme 103).129
The cis-β-amino acid nitroxide derivatives were then
prepared by removal of the chiral auxiliary and N-Fmoc
protection.129 The trans isomer was obtained by epimerization
under basic conditions.129,130
3.1.3.2. Syntheses by Amino Group Conjugate Addition.
Amino group conjugate addition to α,β-unsaturated carboxylic
esters as a general method for the synthesis of cyclic β-amino
acid derivatives (e.g., carbocyclic β-amino acids, described in
section 2.1.3, or ﬁve-membered N-heterocyclic β-amino acids,
presented in section 3.1.2.1) may also be applied for the
construction of β-amino acids with a six-membered N-
heterocyclic framework. Dialkylation of benzylamine with
unsaturated bromoester 504 resulted in diester 506, which on
treatment with chiral (S)-N-benzyl-N-α-methylbenzylamide by
Michael conjugate addition provided piperidine amino
dicarboxylate stereoisomers 507 and 508 in a ratio of
approximately 9:1 (Scheme 104). The stereoisomers were
separated by chromatography and, after removal of the chiral
auxiliary by hydrogenolysis, gave the corresponding piperidine
β-amino esters.21
3.1.3.3. Syntheses by One-Pot Multicomponent Reaction.
Six-membered N-heterocyclic β-amino acid derivatives may be
prepared by a rather novel and special one-pot multicomponent
reaction approach. 4-Methylbenzaldehyde, aniline, and methyl
acetoacetate in the presence of I2 in MeOH underwent one-pot
multicomponent reaction (MCR) to aﬀord highly function-
alized piperidine 509 (Scheme 105);131 however, the carboxylic
Scheme 96. Synthesis of a Pyrrolidine cis-β-Amino Ester by
Curtius Rearrangement
Scheme 97. Synthesis of a trans-Pyrrolidine β-Amino Ester by Curtius Rearrangement
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and amino functions in this product are not connected to
stereogenic carbon centers.
The above method could be generalized by using diﬀerent
aldehydes and anilines, when the transformation was carried
out in the presence of Zr derivatives.132
3.1.3.4. Syntheses by Intramolecular Michael Addition to
Piperidine Carboxylates. Intramolecular conjugate addition of
trichloroimidates to a piperidine α,β-unsaturated ester led to
highly functionalized six-membered N-heterocyclic β-amino
acids. Thus, unsaturated ester 510 was reacted with
trichloroacetonitrile in an intramolecular Michael addition to
give oxazoline derivative 511 (Scheme 106). In the presence of
p-TsOH, pyridine, and H2O, 511 underwent hydrolysis with
oxazoline opening to furnish stereoisomers 512 and 513 in a
ratio of 9:1. After their separation, 512 and 513 were easily
converted by reduction of the trichloroacetate group, followed
by ester and amino group deprotection, to highly functionalized
piperidine β-amino acids 514 and 515 (Scheme 106).133
Other bioactive L-iduronic acid-type 1-N-imino sugar
derivatives similar to 514 have been demonstrated to possess
enzyme inhibitory and antimetastatic activity. A synthetic
protocol to a related compound is presented in Scheme 107.
Unsaturated ester 516 was reacted with Cl3CCN via an
intramolecular Michael addition followed by oxazoline opening
to give 518. After reductive cleavage of the Cl3CCO group
followed by guanylidation of the free amino function and ester
deprotection, the novel highly functionalized piperidine β-
amino acid 521 was obtained (Scheme 107).134
3.1.3.5. Syntheses from Carbocyclic β-Amino Esters by an
Oxidative Ring-Opening−Reductive Ring-Closure Protocol.
β-Amino esters with a piperidine skeleton have been prepared
from their ﬁve-membered unsaturated carbocyclic analogs.
Dihydroxylated amino ester enantiomer 330, prepared as
presented in section 2.4.1.5 by OsO4-catalyzed dihydroxylation,
was a suitable starting material for this purpose. Amino ester
enantiomer (+)-330 underwent oxidative C−C bond cleavage
with NaIO4. The dialdehyde intermediate formed in the
presence of benzylamine and NaCNBH3 participated in
reductive ring closure to aﬀord the corresponding piperidine
β-amino ester enantiomer (−)-522 (Scheme 108).5c
Amino ester (−)-333, a stereoisomer of 330, was trans-
formed analogously in a similar protocol to furnish ethyl trans-
β-aminopiperidinecarboxylate (−)-523 (Scheme 108).135
Scheme 98. Synthesis of a Piperidine β-Amino Ester from the Corresponding Oxo Ester
Scheme 99. Syntheses of cis- and trans-β-Amino Ester
Enantiomers Containing a Piperidine Skeleton
Scheme 100. Synthesis of an Enantiomerically Pure
Orthogonally Protected Piperidine β-Amino Acid from the
Corresponding Oxo Ester
Scheme 101. Synthesis of a Piperidine β-Amino Ester Enantiomer by Reductive Amination of the Corresponding Oxo Ester
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3.1.4. N-Containing Cyclic β-Amino Acids with Larger
Ring Systems. The oxidative cleavage of dihydroxylated
carbocyclic β-amino esters, followed by ring closure with
reductive amination, was eﬃciently applied for the synthesis of
seven-membered N-containing heterocyclic β-amino acids.
Thus, on treatment with NaIO4 and then with benzylamine
and NaCNBH3, 3,4-dihydroxlated ethyl 2-aminocyclohexane-
carboxylate enantiomer 524 yielded azepane β-amino ester 525
in optically pure form. Epimerization of 525 with NaOEt
readily provided the trans stereoisomer 526 (Scheme 109).5d
Another azepane β-amino ester, a regioisomer of 526, could
be prepared from ethyl 4,5-dihydroxylated 2-aminocyclohex-
anecarboxylate 527. Oxidative ring-opening of enantiomer
(−)-527, followed by reductive amination and ring closure,
gave azepane enantiomer (−)-528, a regioisomer of 525, whose
epimerization led to its trans stereoisomer (+)-529 (Scheme
110).5d
N-Containing bicyclic β-amino esters were easily prepared
from norbornene amino esters 530 or 534 by using the above
procedure. Dihydroxylation of di-exo-norbornene ester 530,
followed by oxidative ring cleavage and ring closure under
reductive amination conditions, provided bicyclic β-amino ester
533 (Scheme 111).
Similarly, transformation of di-endo-dihydroxy derivative 534
aﬀorded a mixture of two isomers, the desired 536 and the
earlier prepared 533, which probably resulted from enolization
of the dialdehyde intermediate. After separation, 536 under-
went epimerization to give stereoisomer 537 (Scheme 112).5e
3.2. Syntheses of Cyclic β-Amino Acids with an O Atom in
the Ring
The most abundant of the O-containing cyclic β-amino acids
are those containing an oxetane, tetrahydrofuran, or pyran ring
system. Accordingly, this chapter will focus on the syntheses of
such four-, ﬁve-, and six-membered O-heterocyclic derivatives.
In contrast with the carbocyclic and N-heterocyclic analogs, far
fewer general synthetic methods are available for the synthesis
of these classes of compounds. For this reason, syntheses will
be described for the most representative of these compounds.
3.2.1. Four-Membered O-Containing Cyclic β-Amino
Acids. Isolation of the four-membered O-heterocyclic β-amino
acid antibiotic oxetin (344; Figure 21)92 led to appreciable
interest in the synthesis of functionalized oxetane β-amino acid
derivatives. The main procedure for the preparation of oxetane
β-amino acids starts from various monosaccharides and results
after a number of steps in optically pure target compounds. For
example, L-rhamnose can be converted to hydroxylated ester
539 containing an oxacyclobutane ring in four steps. The
hydroxy group of ester 539 was converted via triﬂate 540 by
inversion with NaN3 to cis-azido ester 541. Transformation of
triﬂate ester 540 by treatment with F3CCO2Cs in butanone
yielded cis-hydroxylated ester 542, which by hydroxy−azide
exchange aﬀorded trans-azido ester enantiomer 543. Both cis-
and trans-azido ester stereosiomers 541 and 543 are
orthogonally protected oxetane β-amino esters (Scheme
113).135
Methyl-substituted oxetane β-azido esters have been
prepared from D-xylose. Bromomethyl ester 545, derived
from monosaccharide 544 in ﬁve steps, was reduced with
Me3SiH to yield 546. This underwent benzoyl ester hydrolysis
to give hydroxylated ester 547, which was ﬁnally converted to
methyl-substituted oxetane cis-β-azido ester 548 (Scheme
114).136
By means of the above procedures, several other substituted
oxetane β-amino acids have been synthetized in optically pure
form (Figure 25).135a,c,137
Scheme 102. Synthesis of Enantiomerically Pure Piperidine β-Amino Ester by Reductive Amination of the Corresponding Keto
Ester
Scheme 103. Syntheses of Chiral β-Amino Acid Nitroxides
Scheme 104. Syntheses of Piperidine Amino Dicarboxylates
by Conjugate Addition to Unsaturated Esters
Scheme 105. Synthesis of a Highly Functionalized Piperidine
β-Amino Ester in a One-Pot Multicomponent Reaction
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Not only carbohydrates but also optically pure α-amino acid
derivatives are suitable precursors for oxetane β-amino acids.
One synthetic pathway started from optically pure tritylserine
(553), which was transformed with the coupling agent BOP
[(benzotriazol-1-yloxytris(dimethylamino)phosphonium hexa-
ﬂuorophosphate] to a lactone intermediate, the methylenation
and oxidation of which resulted in spiro compound 554.
Reduction of 554 with diisobutylaluminium hydride (DI-
BALH) produced oxirane-ring-opened stereoisomers 555 and
556 in a ratio of 2:1, which were then separated (Scheme
115).138
After O-protection by acetylation, followed by N-protecting
group exchange for Boc, amino alcohol 555 aﬀorded 557.
Following deacetylation, 557 was then subjected to hxdrox-
ymethyl group oxidation and N-deprotection to yield β-amino
acid enantiomer 560 (Scheme 116).138
3.2.2. Five-Membered O-Containing Cyclic β-Amino
Acids. Among the ﬁve-membered o-heterocyclic β-amino acids,
the largest groups, the sugar amino acids (SAAs) and the
nucleoside amino acid (NAAs), are biologically important
products.
3.2.2.1. Sugar Amino Acids (furanoid β-amino acids). The
sugar amino acids are carbohydrate derivatives bearing both
Scheme 106. Syntheses of Highly Functionalized Piperidine β-Amino Acid Stereoisomers
Scheme 107. Synthesis of a Guanylidinated Piperidine β-Amino Acid
Scheme 108. Syntheses of cis- and trans-Piperidine β-Amino
Esters from a Carbocyclic Precursor by a Ring-Enlargement
Procedure
Scheme 109. Syntheses of cis- and trans-Azepane β-Amino Esters from a Carbocyclic Precursor by a Ring-Enlargement
Procedure
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amino and carboxylic acid functionalities. They are versatile
glyco- or peptidomimetics of value as conformationally rigid
building blocks in the construction of novel peptides (Figure
26).2a,139
A number of furanoid β-amino acids (e.g., 561 and 562)
possess noteworthy antifungal activities.2a
A series of conformationally rigid enantiomerically pure sugar
β-amino acid stereoisomers has been synthetized and
investigated as bioactive derivatives and also in peptide
chemistry, forming an important bridge between carbohydrates
and proteins (Figure 27).140
The synthesis of sugar β-amino acids starts from diﬀerent
enantiomerically pure carbohydrate derivatives and leads to
optically pure target products.
The preparation of conformationally rigid glutamate analog
lactone β-amino ester 574 was accomplished from optically
pure ribofuranose derivative 570 (methyl 5-O-trityl-β-D-
ribofuranoside). The key steps in the synthesis were
hydroxy−azide exchange at C-3, followed by oxidation of the
hydroxymethyl moiety with NaIO4 in the presence of RuCl3.
The compound obtained, 572, was next converted by
Scheme 110. Syntheses of cis- and trans-Azepane β-Amino Ester Enantiomers from a Carbocyclic Precursor by a Ring-
Enlargement Procedure
Scheme 111. Synthesis of an Azabicyclic β-Amino Ester from
a Carbocyclic Precursor by Ring Enlargement
Scheme 112. Syntheses of Azabicyclic β-Amino Esters from a
Carbocyclic Precursor by Ring Opening−Ring Closure
Scheme 113. Syntheses of Hydroxylated Oxetane β-Amino Esters from L-Rhamnose
Scheme 114. Synthesis of a Methyl-Substituted Oxetane β-
Azido Ester from D-Xylose
Figure 25. Structures of some substituted oxetane β-amino acids.
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intramolecular aziridination followed by aziridine opening with
EtSH to furnish the required heterocyclic β-amino ester
derivative glutamate analog 574 (Scheme 117).141
Glucosamine derivative 575 (2-amino-2,6-dideoxy-α-D-glu-
copyranoside) was the starting material for the synthesis of
lactone β-amino acid 579. Oxidative ring contraction of 575
aﬀorded carboxysulfonamide derivatives 576 and 577 in a ratio
of approximately 1:1. After separation of the two isomers,
removal of the sulfonyl group from 576 in the presence of Li in
liquid NH3 aﬀorded furan β-amino acid derivative 578, which,
after ether cleavage and glycosidic hydroxy group oxidation,
provided 579. β-Amino acid derivative 579 was the precursor in
the synthesis of the antibiotic thienamycin (Scheme 118).142
Furanoid β-azido esters derivatives as ﬁve-membered O-
heterocyclic-protected β-amino acids served as precursors of
functionalized O-heterocyclic β-amino acids, which were key
elements in the construction of various linear or cyclic peptide
oligomers with antiproliferative and multidrug-resistance
activities.
Diacetone glucose (580) was the starting material for the
preparation of enantiomerically pure furanoid β-azido ester
stereoisomers, which may be regarded as protected amino
esters or precursors of the corresponding β-amino acids. The
synthesis is based on hydroxy−azide interconversion, followed
by oxidative transformation of the glycosidic hydroxy group.
Introduction of the azide onto the carbohydrate was achieved
by transformation of its hydroxy function via triﬂate, followed
by displacement with NaN3 to give 581. Diol deprotection with
TFA, followed by mild oxidation of the glycosidic hydroxy,
yielded lactone 582, which was next transformed by acetal
deprotection, triﬂate substitution, and esteriﬁcation to cis-β-
azido ester 583 (Scheme 119).140a
Other cis- or trans-azidotetrahydrofurancarboxylates pre-
sented in Figure 28, stereoisomers of 583 bearing hydroxy
and hydroxymethyl groups, have also been synthetized by the
same research group.143
L-Arabinose was another carbohydrate that furnished novel
optically pure sugar β-azido esters. Ring opening and ring
closure of hydroxy lactone 587 (derived from L-arabinose)
aﬀorded methyl ester 588, which during transesteriﬁcation
through the corresponding carboxylic acid with AcCl resulted
in 589. Hydroxy group protection in compound 589 with tert-
butyldiphenylsilyl chloride (TBDPSCl) yielded monoprotected
derivatives 590 and 591 in a ratio of approximately 1.3:1. After
separation of the two isomers, hydroxy−azide conversion via
the triﬂate in 590 led to β-azido ester enantiomer 592,
possessing a protected hydroxy group at C-4 (Scheme 120).144
Another route that led to a sugar azidocarboxylic acid
enantiomer started from methyl 3-azido-4,6-O-benzylidene-3-
deoxy-α-D-allopyranoside (593). Compound 593, on treatment
with diethylaminosulfur triﬂuoride (DAST) followed by
methanolysis and acetylation, gave furanoid azido sugar 594,
which by ring contraction and subsequent deacetalization and
oxidation furnished β-azido ester 595 (Scheme 121).145
An eﬃcient procedure for the preparation of cis- and trans-β-
azido esters containing a tetrahydrofuran skeleton was
described recently by Pandey et al. Dimethyl acetal derivative
597 (derived from ditosylate sugar synthon 596) underwent
intramolecular tosylate displacement to give epoxide derivative
598. Reductive oxirane opening with DIBALH in THF aﬀorded
regioisomers 599 and 600 in a ratio of 3:1. When the reaction
was performed in CH2Cl2, 7:1 selectivity was attained.
Subsequently, regioisomers 599 and 600 were separated by
means of chromatography (Scheme 122).146
Dimethyl acetal 599 was a suitable starting material for
further transformation to tetrahydrofuran β-amino acids.
Through the corresponding mesylate and treatment with
NaN3, 599 was readily transformed by inversion to 601, the
acetal deprotection and oxidation of which gave azido acid 602.
Esteriﬁcation of 602 with CH2N2 resulted in cis-β-azido ester
603 (Scheme 123). Its trans counterpart (605) was readily
prepared from 604. The synthesis involved oxidation of the
hydroxyl function of 599, followed by oxo group reduction,
which furnished 604, the cis isomer of 599. Hydroxy−azide
Scheme 115. Syntheses of Oxetane Amino Alcohol
Stereoisomers
Scheme 116. Synthesis of a trans-Oxetane β-Amino Acid
from the Corresponding Amino Alcohol
Figure 26. Structures of bioactive tetrahydrofuran β-amino acids.
Figure 27. Some hydroxylated tetrahydrofuran β-amino acid stereo-
isomers.
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interconversion then aﬀorded the required O-heterocyclic trans-
β-azido ester 605 (Scheme 123).146
3.2.2.2. Nucleoside β-Amino Acids. In the large ﬁeld of
nucleosides, the nucleoside β-amino acids are of paramount
importance as bioactive derivatives. Among them, chryscandin
(349; Figure 22), with an adenine nucleobase in its structure, is
a well-known antibiotic. An ever-increasing number of
compounds of nucleoside β-amino acid type have been
reported as selective adenosine A3 agonists; they exhibit
cardioprotective eﬀects and, consequently, are used to prevent
myocardial ischemic injury. The structures of several such
derivatives are shown in Figure 29.147,148
A variety of these derivatives have been utilized as building
blocks in the synthesis of oligonucleotides possessing a β-amino
acid element.147,149
The most general pathways for the syntheses of nucleoside β-
amino acids are those which start from readily available
enantiomerically pure carbohydrate derivatives. Besides func-
tionalization with amino and carboxylic groups, these
procedures involve creation of the nucleobase by means of
diﬀerent methods. Azido sugar 612, derived from glucose
diacetonide, was easily transformed by diol C−C bond
cleavage, oxidation of the formyl group, and amidation to
trans-β-azido amide derivative 613. The latter was next
subjected to reaction with an activated purine derivative,
which led through the glycosidic hydroxy group to 614, bearing
the chloropurine framework. After replacement of the chlorine
on the heteroaromatic ring by methylamine, under reductive
conditions the azido ester readily furnished the corresponding
β-amino amide nucleoside 615 (Scheme 124).139h,148
The synthesis described by Kasinagesan et al. that started
from L-xylose involved as key steps coupling of the sugar
moiety with silylated purine in the presence of trimethylsilyl
triﬂate (TMSOTf) and oxidation of the hydroxymethyl group
to a carboxyl function. Hydroxy protection of amino sugar 616,
followed by acetal cleavage and acetylation, resulted in 618.
After coupling with the silylated nucleobase and cleavage of the
Scheme 117. Synthesis of a β-Amino Ester Containing a γ-Lactone Skeleton
Scheme 118. Synthesis of a Thienamycin Precursor from an Amino Sugar
Scheme 119. Synthesis of a Highly Functionalized
Tetrahydrofuran β-Azido Ester
Figure 28. Structures of highly functionalized tetrahydrofuran β-azido
esters.
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hydroxysilyl protecting group, nucleoside 620 was formed.
Hydroxymethyl oxidation and amidation of the carboxyl group
aﬀorded nucleoside β-amino acid derivative 622 (Scheme
125).150
Aminocarboxylic acid nucleoside 609 was simply synthetized
from azidothymidine (AZT; 623) by hydroxymethyl group
oxidation and azide reduction (Scheme 126).151
The Fmoc-protected thymidine β-amino acid was inves-
tigated as a building block in the construction of peptide
oligomers.152
Scheme 120. Synthesis of a Tetrahydrofuran β-Azido Ester from L-Arabinose
Scheme 121. Synthesis of a Diacetoxylated β-Azido Acid Containing a Tetrahydrofuran Skeleton
Scheme 122. Syntheses of Functionalized Tetrahydrofuran
Regioisomers
Scheme 123. Syntheses of Tetrahydrofuran β-Azido Ester
Stereoisomers
Figure 29. Some bioactive nucleoside β-amino acids.
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Scheme 124. Synthesis of a Nucleoside β-Amino Acid Derivative from an Azido Sugar Precursor
Scheme 125. Synthesis of a Nucleoside β-Amino Acid Derivative from an Amino Sugar Precursor
Scheme 126. Synthesis of an Azidothymidine Analog
Scheme 127. Synthesis of a Tetrahydrofuran β-Amino Acid from a Functionalized β-Lactam
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The simple and eﬃcient route developed by Leemans et al.
for the synthesis of tetrahydrofuran β-amino acids started from
β-bromo imine 625 (readily available from aldehyde 624). The
construction of functionalized β-lactam 626 by the Staudinger
reaction of imine 625 with benzyloxyacetyl chloride in the
presence of Et3N was the key step in the transformation.
Debenzylation of 626, followed by intramolecular nucleophilic
substitution of the bromide aﬀorded bicyclic β-lactam 628, the
lactam ring-opening of which gave ﬁve-membered O-hetero-
cyclic cis-β-amino ester 629 (Scheme 127).153a
A similar strategy was used by the same group of authors for
the synthesis of a nonsubstituted analog of tetrahydrofuran β-
amino ester 629. The starting material in the process, a
hydroxylated imine, was reacted with phenoxyacetyl chloride to
give the corresponding β-lactam, the ring closure of which via
its mesylate followed by lactam opening aﬀorded the required
O-heterocyclic β-amino acid.153b
Amino group conjugate addition (see section 3.1.2.1 for the
synthesis of N-heterocyclic β-amino acids) was also eﬃciently
used for the construction of tetrahydrofuran β-amino acids.
Addition of chiral lithium amides to conjugated unsaturated O-
heterocyclic carboxylic esters aﬀorded enantiomerically pure O-
heterocyclic cis- and trans-β-amino acids with high ee.104
An enantiomerically pure tetrahydrofuran β-amino ester was
recently synthetized from D-mannitol. Compound 630 under-
went Michael addition with allyl alcohol to yield a mixture of
isomers 631 and 632 in a ratio of 4:1. The major isomer was
then subjected to intramolecular nitrile oxide cycloaddition to
furnish isoxazoline 633 as a mixture of two isomers. On
treatment with LiAlH4, this mixture gave amino alcohol
derivative 634 as the major isomer. 634 was next oxidized to
β-amino ester derivative 635. Ketal hydrolysis and diol
oxidative cleavage ﬁnally aﬀorded tetrahydrofuran amino ester
637 (Scheme 128).154
3.2.3. Six-Membered O-Containing Cyclic β-Amino
Acids. 3.2.3.1. Syntheses of Sugar Amino Acids. Amino
sugars are readily accessible, optically pure starting materials for
the synthesis of six-membered β-amino acid sugar derivatives.
One main synthetic approach to pyran β-amino acid sugars
consists of the transformation of amino sugars to β-amino
nitriles, followed by nitrile hydrolysis. Thus, nitrile derivative
639, synthetized from D-glucosamine 638 by hydrolysis,
followed by methanolysis, led through amide 640 to pyran β-
amino ester 641. The latter was then transformed to the
corresponding N-Boc-protected β-amino acid derivative 643
(Scheme 129).155
Azido sugar 644, containing a glycosidic trichloroimidate,
was reacted with trimethylsilyl cyanide (TMSCN) in the
presence of TMSOTf to furnish β-azido nitrile 645, which
served as a precursor for the sugar β-amino acid derivative 647
(Scheme 130).156
Through a similar protocol, azido glucose 648 (derived from
N-acetylglucosamine) was transformed via the imidate to azido
Scheme 128. Synthesis of a Hydroxylated Tetrahydrofuran β-Amino Acid from D-Mannitol
Scheme 129. Synthesis of a Pyran β-Amino Acid from D-Glucosamine
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nitrile 649, which was then easily converted to benzylated sugar
amino acid 651 (Scheme 131).157
Compounds such as 647 or 651 are applied as building
elements in the synthesis of diﬀerent carbopeptoid
oligomers.156,157
Azido amino sugars in the form of orthogonally protected
sugar diamino acids were synthetized from acetylated sugar β-
amino nitrile derivative 652. Deacetalization of 652, with
subsequent exchange of the more reactive hydroxy group at C-6
to azide, resulted in azido nitrile 654, the methoxymethyl
etheriﬁcation of which, followed by nitrile hydrolysis, yielded
azido amino acid 656 (Scheme 132).158
The above synthesis procedure was adopted to prepare
peptidomimetics such as the orthogonally protected diamino
acids 657 and 658 (Figure 30).159
Sugar azido β-amino acid 661 was synthetized from N-
phthaloylamino ester 659 (derived from D-(+)-glucosamine
hydrochloride) through a similar azidolysis at C-6 as the key
step (Scheme 133).159
Enantiomerically pure amino sugars can be transformed into
carbohydrate β-amino acids by lithiation of the corresponding
tributyltin derivatives 664, which were prepared from amino
sugar 662 via N-CBz protection to give 663, followed by
carboxylation of the organometallic intermediate with CO2 as
key steps. After N-Cbz protection, benzylated D-glucosamine
reacted with SOCl2 and tributyltin lithium provided 664, which
was next subjected to lithiation to organometallic compound
665. The latter reacted with CO2 to furnish β-amino acid
derivative 666, in which the arrangement of the amino and
carboxylic groups was trans (Scheme 134).160a The N-
acetylated isomer of 667 was prepared analogously.160b
Through a lithiation−carboxylation strategy similar to the
method presented above, sugar β-amino acid derivative 671, in
which the amino and the carboxylic groups are in the cis
arrangement, was synthetized. O-Benzylated N-acetylgalactose
668 was ﬁrst transformed by inversion at the glycosidic carbon
to α-chlorinated derivative 669. Lithiation with n-BuLi aﬀorded
the corresponding organometallic derivative 670, which
underwent carboxylation to give pyranose β-amino acid
derivative 671 (Scheme 135).161
McGarvey et al. reported another approach for the
preparation of both cis- and trans-tetrahydropyrane β-amino
acid derivatives. For this purpose, alkylidene amino sugar 672
was used as starting material. Dihydroxylation of the C−C
double bond with OsO4, followed by NaIO4-mediated C−C
bond cleavage, aﬀorded aldehyde 673, which in the presence of
K2CO3 underwent isomerization to yield an equilibrium
mixture of epimers 673 and 674 in a ratio of 4:1. Both isomers
(with equatorial or axial formyl groups) were oxidized and
methylated to aﬀord β-amino ester stereoisomers 675 and 676
(Scheme 136).162
Scheme 130. Synthesis of a Pyran β-Amino Acid Derivative
from an Azido Sugar Precursor
Scheme 131. Synthesis of a Pyran β-Amino Acid from an
Azido Sugar Precursor
Scheme 132. Synthesis of an Orthogonally Protected Pyran Diamino Acid from an Amino Sugar Precursor
Figure 30. Structures of some orthogonally protected pyran diamino
acids.
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A number of other sugar β-amino acid stereoisomers (e.g.,
Figure 31) with a pyranose framework have been reported that
are of importance in peptide chemistry (antimicrobial peptides)
and in the construction of bioactive oligosaccharides.163−165
3.2.3.2. Syntheses of Nucleoside β-Amino Acids (blastici-
din and analogs). Analogously to the furanose SAAs, besides
the pyranose sugar β-amino acids, the nucleoside β-amino acids
are of importance as bioactive compounds in medicinal
chemistry. Blasticidin S (isolated from Streptomyces griseochro-
mogenes) is a known fungicide and antibiotic (347; Figure 22).
Other important blasticidin-related nucleoside antibiotics that
contain a β-amino moiety include cytomycin (681), cytosinine
(682), gougerotin analogs (683), and bagougeramine (684)
(Figure 32).166
The syntheses of such derivatives start from readily available
optically pure carbohydrates. Protected amino alcohol 686
containing a pyran skeleton [derived from 2-acetoxy-tri-O-
acetyl-D-glucal (685) in seven steps] was subjected to
hydroxymethyl oxidation and esteriﬁcation to furnish β-amino
ester 687. Removal of the p-methoxyphenyl group followed by
acetylation resulted in 688, which was then reacted through its
glycosidic hydroxy group with a silylated cytosine derivative to
give nucleoside derivative 689. Removal of the trichloroethoxy
carbamate (Troc) group and acetylation resulted in two N-
glycosidic products, which could be separated. Compound 690
was then transformed into blasticidin S and cytosinine
nucleoside antibiotics (Scheme 137).167
A number of blasticidin analogs have been synthetized from
azido sugar 691 (derived from D-galactose in six steps).
Coupling of 691 either with N-acetylcytidine and SnCl4 or
uracil and TMSOTf through its glycosidic acetylated hydroxy
group gave the corresponding nucleoside derivative 692. The
hydroxymethyl group of 692 was then oxidized to yield the
corresponding β-azido carboxylic acid derivative 693, which
was subsequently converted to various blasticidin analogs
(Scheme 138).168
3.2.3.3. Syntheses of Zanamivir Analogs Containing a β-
Amino Acid Moiety. Zanamivir (Relenza) (695), a highly
Scheme 133. Synthesis of a Pyran Azido β-Amino Acid
Scheme 134. Synthesis of a Sugar β-Amino Acid Containing a Pyran Ring from an Aminocarbohydrate
Scheme 135. Synthesis of a Pyran β-Amino Acid from O-
Benzylated N-Acetylgalactose
Scheme 136. Synthesis of a Pyran β-Amino Ester from an Alkenyl Sugar Derivative
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functionalized six-membered O-heterocyclic amino acid, is an
important antiviral agent.169
This bioactive compound has given rise to considerable
increasing interest in medicinal chemistry, and a number of
analogs and other multifunctionalized O-heterocyclic amino
acids have been synthetized and investigated in recent years.
Several of these analogs contain a β-amino acid moiety (Figure
33).60,61
A β-amino acid-modiﬁed zanamivir analog (704) was
synthetized in racemic form by Kerrigan et al. Wittig product
700 (derived from 699) underwent cyclization on reaction with
nitroethanol to furnish the tetrahydropyran β-nitro carbox-
amide derivative 701. Dehydration of 701, followed by nitro
group reduction and acetylation, led to the corresponding β-
amino amide derivative 703, the ester hydrolysis of which gave
the modiﬁed zanamivir target compound 704 (Scheme 139).61b
Another β-amino acid-modiﬁed zanamivir analog was
synthetized from azido zanamivir 706 (a precursor of
zanamivir). Saponiﬁcation of 706 with NaOMe, followed by
C−C bond cleavage with NaIO4, gave the corresponding
aldehyde intermediate, which was subsequently subjected to
oxidation and amidation to furnish β-amino carboxamide 707.
Azide reduction of 707 aﬀorded β-amino acid-modiﬁed
zanamivir analog 708 (Scheme 140).61a
3.2.3.4. Miscellaneous. Six-membered O-heterocyclic β-
amino acid derivative 714 was utilized as an important synthon
in antibiotic chemistry by Hatanaka et al. Its construction
involved the cyclization of unsaturated hydroxylated amino
ester 711 (prepared by the addition of hydroxy ester 709 to
activated imine 710) in the presence of acid to aﬀord pyran β-
amino ester derivative 712. Desulfurization of 712 with
AgNO3/Ag2O in MeOH, followed by ester hydrolysis, provided
714, a precursor of the bioactive daunosamine (715) and
acosamine (716) (Scheme 141).170a
Other intermediates of 714 for the synthesis of carbapenem
antibiotics (thienamycin analogs) were prepared by Ikota et al.
from D-glucose170b or for methylcarbapenem derivatives via the
corresponding methyl-substituted pyran β-amino acid inter-
mediates.170c−e
A further lactone β-amino acid intermediate for access to
thienamycin was prepared by Morley et al. from the
cycloaddition product of an acyl-nitroso compound and
cyclopentadiene, 718. N−O bond cleavage in 718 yielded
protected amino cyclopentenone 719, after which C−C double
bond functionalization with lithiated trimethylsilyl thioacetal
nucleophile and methylation of the active methylene group
gave 720. Desilylation with n-Bu4NF aﬀorded 721, which
underwent oxidation through its masked formyl function and
then esteriﬁcation to give β-amino ester derivative 722.
Oxidative rearrangement of 722 under Baeyer−Villiger
conditions resulted in a δ-lactone β-amino ester as a precursor
for the synthesis of thienamycin (Scheme 142).171
trans-3-Aminopyran-2-carboxylic acid, a building element in
the construction of α/β-peptides, was synthetized from amino
alcohol 725 (derived from enantiomerically pure aldehyde
724). The key step in the synthesis was cyclization of diene
derivative 726 (prepared from 725 by O-alkylation with allyl
Figure 31. Structures of some bioactive sugar β-amino acids.
Figure 32. Structures of some nucleoside β-amino acid antibiotics.
Scheme 137. Synthesis of a Blasticidin S Precursor
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bromide) by metathesis, furnishing O-heterocyclic amino
alcohol 727. 727 was next converted by protecting group
removal to 729, the hydroxymethyl function in which was
oxidized by Swern oxidation, followed by treatment with
NaClO2, to give the required pyran amino acid 731 (Scheme
143).172
cis-3-Aminopyran-4-carboxylic acid (737) was synthetized by
Duan et al. from unsaturated alcohol 733 through reaction with
sodium iodoacetate and MeI. Reduction of the ester
intermediate with DIBALH aﬀorded aldehyde 734. Intra-
molecular dipolar cycloaddition of the nitrone intermediate
obtained from aldehyde 734 led to the key compound, bicyclic
isoxazolidine 735. Debenzylation of 735, hydroxymethyl
oxidation, and esteriﬁcation aﬀorded pyran β-amino ester 737
(Scheme 144).127 cis-3-Aminopyran-2-carboxylic acid, a re-
gioisomer of amino ester 737, was prepared by the same group
from the six-membered O-heterocyclic oxo ester, by means of
reductive amination with (R)-α-methylbenzylamine.173 These
heterocyclic β-amino esters were utilized as building elements
for the synthesis of a series of products with TACE inhibitor
activities.127,173
3.3. Cyclic β-Amino Acids with Other Heteroatoms in the
Ring
In comparison with the N- or O-heterocyclic β-amino acids, the
number of counterparts containing heteroatoms other than N
or O is very low, and only a limited number of publications
have dealt with the synthesis of such compounds.
Amino group conjugate addition to conjugated unsaturated
esters is a convenient route for access to S-heterocyclic β-amino
acid derivatives (for N-heterocycles, see section 3.1.2.1).
The reaction of ethyl thioglycolate with tert-butyl acrylate in
basic medium aﬀorded tert-butyl 4-oxotetrahydrothiophene-3-
carboxylate 739, which led via hydroxy ester 740 after
dehydration with PPh3 and diisopropyl azodicarboxylate
(DIAD) to unsaturated ester 741. Addition of lithium
dibenzylamide to 741 provided a mixture of cis- and trans-β-
amino ester derivatives 742 and 743 in a ratio of 54:46 in an
overall yield of 49% together with isomerized ester 744. On
treatment with t-BuOK in t-BuOH, 742 underwent quantitative
epimerization to furnish 743 (Scheme 145).104
The ﬁve-membered S-heterocyclic β-amino acid regioisomers
depicted in Figure 34 have been investigated as potential
antifungal agents.2a
Six-membered S-heterocyclic derivatives have been synthe-
tized by Diels−Alder cycloaddition between methyl acrylate
(748) and 1-thiobuta-1,3-diene 747. The cycloaddition gave cis-
and trans-tetrahydrothiazine β-amino esters 749 and 750 in a
ratio of 9:1. In the presence of Zn-, Mg-, or Al-based Lewis
acids, cis derivative 749 suﬀered epimerization to trans
derivative 750 (Scheme 146). When chiral oxazolidinone-
based unsaturated amines were used in the above reaction,
enantiomerically pure products were prepared.174
The synthesis of Si-based heterocyclic derivatives started
from Ph2SiCl2 by reaction with vinylmagnesium bromide in the
presence of Cp2TiCl2, which aﬀorded heterocyclic compound
751. Aziridination of 751 with chloramine-T and phenyl-
trimethylammonium tribromide (PTAB) resulted in 752.
Aziridine opening with Et2AlCN provided amino nitrile
derivative 753, which was next converted by Boc protection
Scheme 138. Synthesis of Blasticidin S Analogs from an Azido Sugar
Figure 33. Structures of zanamivir and several β-amino acid-modiﬁed
zanamivir analogs.
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and tosyl group removal to 755. Boc protecting group removal
and ester hydrolysis in the ﬁnal step gave the Si-heterocyclic β-
amino acid 757 (Scheme 147).175
4. SOME RELEVANT BIOLOGICAL PROPERTIES OF
CYCLIC β-AMINO ACIDS
Although a description of the synthetic methodologies was the
main goal of the present review, the present brief section is
intended to oﬀer an insight into the most important biological
properties of cyclic β-amino acids, which may be of interest for
medicinal chemists.
4.1. Cyclic β-Amino Acids Possessing Antifungal or
Antibacterial Properties
Among the most relevant cyclic β-amino acids are those that
exhibit antifungal and antibacterial activities. The two most
representative compounds in this respect as strong antifungal
agents are the ﬁve-membered carbocyclic compounds cispenta-
cin (1) (isolated from the culture broth of a Bacillus cereus
strain) and icofungipen (2) (active against Candida species).
The six-membered unsaturated counterpart BAY Y9379 (3) has
been reported to possess similar pharmacological proper-
ties1,2a−e Not only alicyclic but also ﬁve-membered heterocyclic
Scheme 139. Synthesis of a Racemic β-Amino Acid-Modiﬁed Zanamivir Analog
Scheme 140. Synthesis of a Zanamivir Analog Containing a β-Amino Acid
Scheme 141. Synthesis of a Pyran β-Amino Acid As a Precursor of Several Antibiotics
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β-amino acids exert antifungal and antibacterial activities. An
important class are those with the N-heterocyclic pyrrolidine
core (345), including the stereo- and regioisomers 758 and
759.2a,176 These compounds have been applied as building
elements for the construction of antimicrobial peptide
oligomers.93 Among the antifungal β-amino acids with a simple
structure similar to that of cispentacin are those with an O (561
and 562)2a or S (745 and 746)2a atom in their ring. Several of
their substituted derivatives have been reported to possess
multidrug-resistance activity.139 The four-membered O-hetero-
cyclic derivative oxetin (344) (isolated from a fermentation
broth of Streptomyces sp. OM-2317), a cyclic β-amino acid with
a simple core, is a known antibiotic.92 Several other six-
membered O-heterocyclic analogs (677−680) have been
Scheme 142. Synthesis of a β-Amino Acid Containing a δ-Lactone Ring
Scheme 143. Synthesis of a Pyran β-Amino Ester from a Diene Ether Derivative
Scheme 144. Synthesis of a Pyran β-Amino Ester from a Pyran-Fused Isoxazolidine
Chemical Reviews Review
dx.doi.org/10.1021/cr300454h | Chem. Rev. 2014, 114, 1116−11691161
incorporated in antimicrobial peptides. A functionalized
carbocyclic β-amino derivative containing a hydroxy group
and three chiral centers, oryzoxymycin (238) (isolated from a
soil sample of Streptomyces venezuelae var. oryzoxymyceticus),
exhibits moderate activity against Xanthomonas oryzae, a Gram-
positive bacterium, and has been described as an important
antibacterial agent.1 The cyclic β-amino acids are not only
pharmacologically active compounds themselves but are also
elements in bioactive substances with more complex structures.
Thus, amypurimycin (5) and pitucamycin (6), with ﬁve- and
six-membered carbocyclic β-amino acid moieties, respectively,
in their structure are antibiotics.2g−k A large family of bioactive
compounds is the nucleoside-based antibiotics, whose
structures contain either ﬁve- or six-membered O-heterocyclic
β-amino acid residues. Chryscandin (349) (produced by
Chrysosporium pannorum 4629), a peptide-based nucleoside
derivative with a 3-aminotetrahydrofuran-2-carboxylic acid unit
in its structure, expresses strong antifungal and antibacterial
activities.95 Antibacterial amino acid nucleosides whose
structures include a β-amino acid moiety and a pyran ring
have been synthetized in a relatively large number of diﬀerent
derivatives. Among them, the antibiotic blasticidin S (347),
isolated from Streptomyces griseochromogenes, is probably the
most important example. A number of other amino acid
nucleoside derivatives, such as gougerotin (isolated from
Streptomyces gougerotii) and analogs with diﬀerent functions
(348 and 683), cytomycin (681) (produced by Streptomyces sp.
HKI-0052), cytosinine (682) (hydrolyzed from calf thymus
tissues), and bagougeramine A (684) (produced by a strain of
Bacillus circulans), are antibacterial substances related to
blasticidin S.166
4.2. Antiviral Cyclic β-Amino Acids
Besides their antibacterial properties, the other signiﬁcant
pharmacological feature of cyclic β-amino acids is related to
their antiviral activities. Investigations on the cyclic β-amino
acids in this sense are closely related to their drug counterparts,
such as Relenza169 or Tamiﬂu.59 Some highly substituted
cyclohexanecarboxylic β-amino acids, modiﬁed analogs of
Tamiﬂu (241−244), have been described to display promising
antiviral properties. A number of O-heterocyclic β-amino acid
analogs of Relenza (696−698) have also been synthetized and
investigated as potent antiviral agents with inhibitory action
against inﬂuenza virus sialidases.59−61 Five-membered N-
heterocyclic β-amino acids are another important class of
products that exert antiviral properties. Some of these
pyrrolidine β-amino acids, such as 386 (A-87380) or 387 (A-
192558), possess inﬂuenza neuramidase inhibitory activity.
Through change of the functional moieties either on the amine
nitrogen or on the amide nitrogen, a series of other related
derivatives (758−761, Figure 35) has been synthetized and
investigated as potential inﬂuenza neuramidase inhibitors.104,110
4.3. Cyclic β-Amino Acids with Antitumoral Properties
Although β-amino acids themselves in general do not display
antitumoral activity, they are often elements of many
Scheme 145. Syntheses of Tetrahydrothiophene β-Amino
Esters
Figure 34. Structures of bioactive tetrahydrothiophene β-amino acids.
Scheme 146. Syntheses of Thiopyran β-Amino Esters
Scheme 147. Synthesis of a Si-Heterocyclic β-Amino Acid
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compounds that do possess this property. Thus, norbornene β-
amino acid is an element of CEP-28122 (7), while cyclohexene
β-amino acid is a component of MK-6892 (8). Cyclohexene or
cyclopentane β-amino acid moieties are found in several other
related compounds that exhibit antitumoral properties (9−
11).2 A series of products containing a carbocyclic or
heterocyclic β-amino acid residue has been synthetized and
evaluated as eﬃcient selective inhibitors of tumor necrosis
factor (TNF-α) converting enzyme (TACE). Apart from those
in which there is a carbocyclic β-amino acid (e.g., 9),127 the
most abundant are those with a pyrrolidine β-amino acid
framework. Five-membered N-heterocyclic β-amino acid or
hydroximic acid-containing molecules and related substituted
derivatives93,94 4192k and 762−767 (Figure 36), for example,
are representative molecules of this type.109,177
The six-membered N-heterocyclic β-amino acids and the
pyran β-amino acids may also function as elements of
molecules with TACE inhibitor activity (e.g., 765).127,173,177
Highly functionalized piperidine β-amino acid derivatives (514,
515, and 768) act as enzyme inhibitors and exhibit
antimetastatic activity,134 while pyrrolidine-based β-amino
acid derivatives with structures such as 769 behave as
dipeptidyl-peptidase IV inhibitors (Figure 37).178
4.4. Cyclic β-Amino Acids with Cardioprotective Properties
Nucleoside β-amino acids (606−611) are not only antibacterial
agents, but are also used as selective adenosine A3 agonists for
the treatment of certain myocardial diseases, for instance, to
prevent myocardial ischemic injury. A relatively large number of
variously substituted derivatives of these types of compounds
have been described in recent years.146
5. SUMMARY AND OUTLOOK
As reﬂected by the increasing number of publications devoted
to alicyclic and heterocyclic β-amino acids during the past 15
Figure 35. Some pharmacologically important pyrrolidine β-amino
acids.
Figure 36. Some antitumoral compounds with a heterocyclic β-amino acid element.
Figure 37. Structures of N-heterocyclic β-amino acids that act as
enzyme inhibitors.
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years, this ﬁeld has become an expanding area in organic and
medicinal chemistry. In particular, the biological characteristics
of the cyclic β-amino acids as independent molecular entities,
together with their usage as precursors of diﬀerent heterocycles,
as chiral auxiliaries in asymmetric syntheses, and as precursors
of β-lactams and in foldamer chemistry, have aroused immense
interest in chemistry and in drug research, and the synthetic
procedures devised for access to these and related derivatives
have developed tremendously. The presence of β-amino acid
frameworks in various bioactive natural products may be
expected to lead to increasing interest in the discovery of novel
routes and methodologies for their preparation in enantiomeri-
cally pure form. The substituted derivatives of cyclic β-amino
acids as analogs of known antiviral agents appear sure to exert a
great impact on drug discovery and the future synthesis of
potential bioactive peptides. Novel synthetic pathways to highly
functionalized derivatives, e.g., by the selective transformation
of ring oleﬁnic bonds with the generation of multiple
stereogenic centers, and their conversion via carbocycle-
opening procedures, followed by an abundance of functional-
ization (oxido-reductive techniques, metathesis, etc.), will
certainly be topics of enormous interest to synthetic chemists.
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ABBREVIATIONS USED
AIBN = azobisisobutyronitrile
Ac = acetyl
ACPC = 2-aminocyclopentanecarboxylic acid
AZT = azidothymidine
9-BBN = 9-borabicyclo[3.3.1]nonane
Boc = tert-butoxycarbonyl
BOP = (benzotriazol-1-yloxytris(dimethylamino)-
phosphonium hexaﬂuorophosphate
CAL-B = Candida antarctica lipase B
CAN = cerium ammonium nitrate
COD = cyclooctadiene
Cp = cyclopentadienyl
CSI = chlorosulfonyl isocyanate
DAST = diethylaminosulfur triﬂuoride
Deoxo-Fluor = bis(2-methoxyethyl)aminosulfur triﬂuoride
DBU = 1,8-diazabicycloundec-7-ene
DEAD = diethyldiazodicarboxylate
DIAD = diisopropyldiazodicarboxylate
DIBALH = diisobutylaluminium hydride
DIPEA = diisopropylethyl amine
DMAP = 4-dimethylaminopyridine
DMB = dimethoxybenzyl
DMDO = dimethyldioxirane
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DMF = N,N-dimethylformamide
DMPU = 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidi-
non
DPPA = diphenylphosphoryl azide
EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
Fmoc = ﬂuorenylmethoxycarbonyl
HMPA = hexamethylphosphoramide
HOAt = 7-aza-1-hydroxy-1,2,3-benzotriazole
IBCF = isobutyl chloroformate
KHMDS = potassium hexamethyldisilylamide
LDA = lithium diisopropylamide
LiHMDS = lithium hexamethyldisilylamide
mCPBA = m-chloroperbenzoic acid
Ms = methanesulfonyl
NAAs = nucleoside amino acids
NBS = N-bromosuccinimide
NaHMDS = sodium hexamethyldisilylamide
NIS = N-iodosuccinimide
NMM = N-methylmorpholine
NMO = N-methylmorpholine N-oxide
Ns = p-nitrosulfonyl
PDC = pyridinium dichromate
PLE = pig liver esterase
PMB = p-methoxybenzyl
PMP = p-methoxyphenyl
PTAB = phenyltrimethylammonium tribromide
p-Ts = p-toluenesulfonyl
Py = pyridine
SAAs = sugar amino acids
TBDMS = tert-butyldimethylsilyl
TEMPO = 2,2,6,6-tetramethylpiperidinyloxy
Tf = triﬂuoromethanesulfonate
TFA = triﬂuoroacetic acid
TMS = trimethylsilyl
TolBINAP = 2,2′-p-tolylphosphino-1,1′-binaphthyl
Tr = trityl
Troc = trichloroethoxy carbamate
Z = benzyloxycarbonyl
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17, 1129. (q) Forro,́ E.; Fülöp, F. Tetrahedron: Asymmetry 2006, 17,
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T. A.; Fülöp, F. Chem. Soc. Rev. 2012, 41, 687. (g) Mansawat, W.;
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26, 4993.
(70) Songis, O.; Didierjean, C.; Martinez, J.; Calmes, M. Tetrahedron:
Asymmetry 2008, 19, 2135.
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F. Tetrahedron: Asymmetry 2010, 21, 957.
(86) Kiss, L.; Nonn, M.; Forro,́ E.; Sillanpaä,̈ R.; Fülöp, F.
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(88) (a) Nonn, M.; Kiss, L.; Sillanpaä,̈ R.; Fülöp, F. Beilstein J. Org.
Chem. 2012, 8, 100. (b) Kiss, L.; Nonn, M.; Fülöp, F. Synthesis 2012,
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